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Abstract
Helicobacter pylori infects more than 50% of the world population and is acquired in infan‐
cy. Higher prevalence is found in developing countries, and within geographic areas the
predominance correlates inversely with socioeconomic status, especially with living con‐
ditions during childhood. Initially, in adults, H. pylori was only associated with gastric
diseases, such as peptic ulcer, gastritis, gastric adenocarcinoma, and gastric mucosa-asso‐
ciated lymphoid tissue (MALT) lymphoma, and in childhood, with chronic gastritis and
duodenal ulcers in children. Recently, H. pylori has been related to non-gastric diseases,
including hematological disorders such as iron deficiency anemia (IDA), chronic idio‐
pathic thrombocytopenia (cITP), and vitamin B12 deficiency. H. pylori can trigger autoim‐
mune atrophic gastritis and be responsible initially for an oral iron refractory anemia.
Other hematological associations have been made, such as an increased risk of childhood
leukemia in children of H. pylori-infected mothers and gastric bleeding in children with
coagulation pathologies. H. pylori infection is important in the immune pathogenesis of
chronic gastric inflammation and hematological diseases. The diagnostic methodology is
based on non-invasive (serology, C-urea breath test, stool HP antigen) and invasive tests.
The scientific community discussed and incorporated in international consensus for the
investigation and management of these hematological extragastric pathologies (IDA,
cITP, vitamin B12 deficiency, and MALT lymphoma). In children, a similar attitude was
obtained in all of these pathologies except for cITP, in which the investigation for H. pylo‐
ri is not indicated.
Keywords: Helicobacter pylori, iron deficiency anemia, immune thrombocytopenia, MALT
lymphoma, vitamin B12 deficiency
1. Introduction
Helicobacter pylori is a gram-negative spiral bacterium, responsible for one of the most frequent
gastrodigestive infections in the world. In 1883, Bizzozero reported spirochetes inhabiting the
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gastric glands of dogs [1]. However, in 1954, after examining 1000 gastric biopsies, Palmer
concluded that no microorganisms could survive in an acidic gastric environment [2]. This
was contradicted by Marshall and Warren in 1982 [2].They isolated the microorganism from
the specimens of gastric mucosa in patients with gastritis and peptic ulcers, and for the first
time it was isolated in vitro culture. As previously stated, at that time, it was thought that the
acidic gastric environment was not compatible with the survival of this bacterium. In 1991, an
association between H. pylori infection and gastric mucosa-associated lymphoid tissue (MALT)
lymphoma was found [3]. Then, in 1994, The National Institute of Health consensus conference
in the United States declared an association between H. pylori infection and peptic ulcer disease
[4]. In that same year, H. pylori was identified with gastric adenocarcinoma and gastric non-
Hodgkin lymphoma [3, 4].
After the discovery made by Marshall and Warren, histological features of chronic gastritis in
upper gastrointestinal endoscopy were revealed. Moreover, a Canadian group also found H.
pylori in the gastric mucosa of children with gastritis and duodenal ulcers [5].
Although over 80% of infected subjects remain asymptomatic, H. pylori chronic infection is
associated with different clinical manifestations, including chronic gastritis, peptic ulcer
disease, lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma. Furthermore, in
1994, H. pylori was classified as a type 1 carcinogen by the World Health Organization (WHO)
[6-8]. In children, H. pylori has been considered a cause of chronic gastritis and duodenal ulcers.
Recently, it has been related to diseases outside the stomach, namely those characterized by
persistent and low-grade systemic inflammation: iron deficiency anemia (IDA), chronic
idiopathic thrombocytopenia (cITP), vitamin B12 deficiency, growth retardation, and diabetes
mellitus [9, 10]. Although a relationship between the H. pylori infection and autoimmune
atrophic gastritis (AAG) is not possible, studies conducted by Hershko proved that H. pylori
can be the trigger of AAG and be responsible in the initial phase of the disease for an oral
refractory iron anemia [11-14]. More debated hematological associations have been made with
monoclonal gammopathy, non-Hodgkin lymphomas of the stomach, myelodysplastic
syndromes, increased risk of childhood leukemia in the children of H. pylori-infected mothers,
and gastric bleeding in children with coagulation pathologies [15-17].
The H. pylori infection is acquired during childhood (before the age of 10) and in the absence
of antibiotic therapy the host can carry it for life. In contrast to the great majority of bacterial
infections, in which virulence is temporary due to an immune system mechanism, which
results in the clearance of the pathogen, H. pylori can survive for many years [15-18]. H.
pylori has mechanisms to escape the clearance of the innate and adaptive immune system, and
the development of a symbiotic relationship between the bacteria and the human host is also
a possibility [9-12]. Moreover, H. pylori has an important urease activity, leading to ammonia
production in order to protect itself from gastric acidity. Also, H. pylori produces enzymes,
such as phospholipase A2 and C as well as glycosulphatase, which leads to gastric mucosa
damage [6].
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2. The interaction between H. pylori and the immune system
Epithelial and myeloid cells form the initial line of the innate immune system response against
H. pylori infection. They recognize the bacteria through a limited number of microbial pattern
recognition receptors (PRRs), which include membrane associated Toll like receptors (TLRs),
cytoplasmic Nod-like receptors (NLRs) and retinoic acid inducible gene I-like helicase receptor
(RLRs). They recognize bacteria constituents termed pathogen-associated molecular patterns
(PAMPs), present in the microbial proteins, nucleic acids, lipids and carbohydrates. These
PAMPs contain molecules that act as ligands to trigger PRRs dependent intracellular signaling
pathways, inducting the expression of pro-inflammatory molecules and cytokines as the first
response to the bacteria infection. TLRs are the most studied of the larger family of the PRRs
and participate in the first line of host defense against pathogens, with subsequent activation
of adaptive immune response [17-21]. Ten TLRs have been identified in humans and can be
identified by the type of ligand [12-14]. TLRs are type I transmembrane proteins characterized
by an extracellular leucine-rich ectodomain involved in PAMP recognition from bacteria,
fungi, parasites, and viruses, including lipid components of wall cell bacteria such as lipopo‐
lysaccharides (LPS) and lipopeptides, microbial components such as flagellin and nucleic acid
components, as well as an intracytoplasmatic domain that shows similarity to the IL1 receptor
family termed a toll-IL1 receptor (TIR), which is involved in the activation of downstream
signaling pathways. TLRs are expressed on the surface of cells or in intracellular vesicles like
endosomes [18, 19, 22, 23]. Some TLRs recognize only one type of PAMP, while others such as
TLR2 recognize bacterial lipoproteins, lipoteichoic acid and peptidoglycans [21]. The Goldberg
Group revealed the role of TLRs during H. pylori infection, showing an overexpression of TLR2
and TLR5 in the gastric epithelial cells HEK293 of H. pylori-infected patients, as well as an
increase of the activation of transcriptional factors: (1) nuclear factor-κB (NF-κB) and inter‐
leukin-8 (IL-8), (2) macrophage inflammatory protein 3α (MI-3α), and (3) the growth-regulated
protein-α (GRO-α mRNA expression) [8]. The understanding of the role of TLRs in response
to H. pylori infection requires an elucidation of cell-signaling events. After PAMP recognition,
TLRs trigger the signaling pathways resulting in: (1) activation of the transcription of NF-B,
protein-1 (AP-1), and of interferon regulatory factors (IRFs); (2) increased expression of
inflammatory cytokines, antimicrobial peptides, and interferon type 1 (INF-1); and (3)
recruitment of neutrophils, activation of macrophage, and dendritic cells. In epithelial cells,
studies have found an increased induction of pro-inflammatory genes caused by the interac‐
tion between H. pylori and 4TLR [18, 19, 22, 23].
MyD88 (myeloid differentiation primary response protein 88) is an intracellular adaptor
protein used by all TLRs except TLR3, and the signaling is done in two forms: MyD88
dependent, responsible for pro-inflammatory cytokine production as well as MyD88 inde‐
pendent, responsible for interferon type 1 production (ITF1). TLR4 inducts both dependent
and independent MyD88, so it inducts both cytokines and ITF1. The expression of MyD88 in
macrophage cells is essential for the induction of anti-inflammatory cytokines (IL-6, IL-1B,
IL-10, and IL-12) [19]. Recently, a new group of innate immune molecules, including activating
receptors involved in modulating the intensity of innate immune response in myeloid cells
(TREM), has been described [24, 25]. TREM family receptors (TREM-1 to TREM 4), are cell
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surface activating receptors with a transmembrane region containing charged lysine residues
and a short cytoplasmatic tail lacking signaling motifs. TREM-1, a 30-Kda glycoprotein of the
Ig family is the most well-known member of the TREM family and is responsible for inflam‐
mation amplification and activation of antigen-presenting cells (APC). TREM-1 is exhibited in
neutrophils and monocytes and linked to innate immunity by phagocyte secretion of pro-
inflammatory chemokines and cytokines such as IL-8 and TNF-α. TREM-1 is involved in the
amplification of TLR-dependent signals and in the improvement of NOD-like receptors
(NLRs)–mediated responses, including NOD-1, involved in the protection against H. pylori
infection [19]. An up-regulation of TREM-1 in gastric epithelial cells of H. pylori infected adults
patients was found in a study by Schmausser et al. using immunohistochemistry in nine of
twelve patients. No TREM-1 was found in non-inflamed gastric epithelium, in accordance with
mRNA, TREM-1 also strongly expressed in H. pylori gastritis. [19, 26]. These results are not in
accordance with Michalkiewics study done in 78 children with H. pylori infection. The gastric
expression of TREM-1 and TREM-2 was not affected by H.pylori infection, reflecting the
tolerance status of leucocytes present in gastric mucosa of H pylori infected children [19].
TREM-2 is expressed in macrophage and dendritic cells, acts antagonistically to TREM-1 and
its activation results in anti-inflammatory reactions. This receptor has not yet been observed
in H. pylori-infected patients. M1 macrophage cells are linked to strong pro-inflammatory and
cytotoxic responses induced by INFγ, tumor necrosis factor (TNF), and IL-6. M2 macrophage
cells show markers of an anti-inflammatory process through CD163, a cell surface glycoprotein
whose expression is induced by inflammatory mediators, such as glucocorticoides and IL-10.
Also, they are inhibited by pro-inflammatory mediators, such as INFγ, TNF-α, as well as others
[18, 19, 22, 23]. The CD14 receptor is a cell surface molecule expressed on monocytes and
macrophages and linked to the recognition of H. pylori LPS, which leads to the production of
many pro-inflammatory cytokines. The interaction of H. pylori and CD14 shows that its
expression in gastric mucosa may indicate infiltration by monocytes/macrophages [27]. On the
other hand, H. pylori has two major factors for virulence, vacuolating cytotoxin (VacA) and H.
pylori neutrophil-activating protein (H. pylori-NAP), related to the stimulation of radical
oxygen production by neutrophils. H. pylori-NAP is a 150-KDa oligomeric protein, a TLR2
agonist that exhibits chemotaxis for the neutrophils and monocytes, increasing the synthesis
of tissue factor and type-2 plasminogen inhibitor, IL-23, and IL-12, a key cytokine for the
differentiation of naïve T helper (TH) cells into the TH1 cytotoxic phenotype. Naïve T CD4+
helper TCD4+ cells can be called to differentiate towards TH1, TH2, TH17, and regulatory T
cells (Tregs) phenotypes according to the cytokines. Classically, TH cells are divided into two
functional subsets: Th1 and Th2, responsible for the production of a distinct pattern of cytokine
secretion. The adaptive system produced by the host against H. pylori includes Th1 and Th17
components that are implicated in the control of infection. Despite these data, a number of
reports suggest that this Th1-biased response is dysfunctional and can be considered as an
important role in pathogenesis of H. pylori-related diseases [23, 27, 28]. Indeed the immuno‐
modulatory properties of the pathogen can reprogram the host’s immune tolerance and H.
pylori escapes [19]. In a study published by Michalkiewics, 78 children, ranging in ages between
7 and 18 years, with a confirmed H. pylori infection in 40 patients (50% without symptoms), a
Th1 profile of H. pylori-mediated inflammation was found [28]. H. pylori can modulate MyD88
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expression. In other words, the lack of significant amounts of MyD88 can explain the persis‐
tence of the infection and the endotoxin tolerance [19]. Furthermore, the exact role of T Helper
cells in H. pylori infection is not fully understood. Recent studies revealed that a deficiency in
Th1 response may be responsible for the persistence of H. pylori infection [28, 29]. The role of
H. pylori in pathogenesis of extra-gastroduodenal diseases may be based on the systemic effects
of chronic gastric inflammation immune responses, which can induce lesions outside of the
stomach and can be reversed after H. pylori eradication [10, 14-16].
3. Epidemiology and risk factors
More than 50% of the world’s population is infected with H. pylori [7, 8, 30]. Although infection
occurs worldwide, its prevalence shows a marked discordance within and between developed
and developing countries. Overall prevalence oscillates between 30 and 50% in industrialized
countries, in contrast with the ranges of 80–90% found in the developing countries. Within
geographic areas, the predominance correlates inversely with socioeconomic status, especially
those related with living conditions during childhood. The improvement in hygiene, sanitary
conditions, and the active treatment of the H. pylori carrierships implemented in developed
countries may be the responsible for the difference in these two worlds [6, 7, 17, 31-34]. Reports
regarding racial and ethnic differences in the prevalence of H. pylori infection in children and
adults have been carried out. Everhart et al. reported an overall seropositivity rate of H.
pylori infection in 32.7% of 7465 adult participants in the United States. Higher prevalence was
observed in non-Hispanic blacks and Mexican Americans (51.1 and 57.9%, respectively),
compared with the values observed among non-Hispanic whites (26.9%) [29]. A study
conducted by Nguyen et al. in two ethnic groups (Kinh and Khmer), with different cultures,
involving 1596 individuals, 485 households, the seroprevalence was higher in adults than in
children ≤18 years (40.2 and 32.1%, respectively). Variables related to promiscuity such as
taking foods by hands, absence of good practice of hand washing after defecation, having
mother or siblings infected by H. pylori were risk factors. There were no differences in H.
pylori seropositivity based on sex (P>0.05) or ethnicity (P>0.05) [31]. In southern China, the
prevalence of H. pylori infection in Chinese people was significantly higher than in Australians
(44.2 vs. 21%). Comparing the prevalence of infection in children aged <10 years, the Chinese
showed 27% and the Australians 4%. In children over the age of 10, a similar rate of H. pylori
acquisition was observed in both countries (1% per annum), according to epidemiological data
[32]. Cherian conducted a cross-sectional study in 193 African refugee children (aged <16 years)
in Western Australia. The mean age was 7.9 years, and 18 children (9%, mean age of 11.3
months, and SD 5.2 months) were breastfeeding. There were 116 children living in refugee
camps and the remaining lived in apartments or houses. The great majority came from
Tanzania or Kenya, 96 of 97 (99%), lived in the camps, whereas 28 originating from Egypt lived
in apartments and houses. H. pylori was present in 82% of children (63% aged <2 years), rising
to 95% for those older than 14 years, confirming a greater risk in Africa. Intrafamilial spread
of H. pylori, particularly mother-to-child transmission or infected older siblings, was a potential
mechanism of this acquisition. Concerning the breastfeeding children, a statistically significant
correlation was not possible because the number of children was small. Curiously, those
children who had done antimalarial treatment seemed to have eradicated H. pylori. It was
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attributed to a probable effect of artemisinin on the iron dependence of the bacteria [33].
Differences in the prevalence of H. pylori infection among racial and ethnic groups have been
described. Besides ethnicity, the difference in the prevalence between developed and devel‐
oping countries seems to be linked to socioeconomic factors. Poverty and bad living conditions
are the principle risk factors for acquiring H. pylori infection within industrialized countries
[6-8, 34-36]. A high number of residents in the same home, sharing the same room or the same
bed with H. pylori-infected children, as well as poor sanitary conditions were identified as
major risk factors [6-8]. This infection is acquired in childhood and they are carrying the same
strain as their parents and maintain this genotype even after moving to a different environment
[37, 38]. In relation to the prevalence based on gender, differences have not been found between
men and women, and no association with smoking or drinking habits has been made [6].
Nutritional status has been described as being associated to H. pylori infection. Goodman et al.
found reduced odds of risk of H. pylori infection in adults and children with an increased
ingestion of fruit, vegetables, and milk. The increased improvement of hygiene at home, as
well as socioeconomic conditions, has resulted in a lower rate of H. pylori infection and an
increase of gastroesophageal reflux disease (GERD) [8, 32, 35-37]. Studies revealed that gastric
corpus inflammation induced by H. pylori, more pronounced with CagA+ strains, has an acid-
suppressive effect, preventing the development of GERD. Also, asthma and allergy disorders
are prevalent in developed countries and inversely associated with H. pylori [8, 14-16, 33, 34,
36]. Hygiene reduces the exposures to microorganism modifiers polarized Th1/Th2 responses
leading to asthma. H. pylori can alter the polarized Th1/Th2 through dendritic cell-mediated
T expression of IL-2, TNF-α, and INF-γ. Longitudinal studies revealed that asthma is a risk
factor to GERD development and GERD can trigger asthma [36, 37]. The most well-known
hematological pathology linked to H. pylori infection in children is IDA. Epidemiological
studies have indicated that seropositivity is associated to low serum ferritin and hemoglobin
levels compared with seronegative controls. Reports have been carried out concerning
refractory iron deficiency anemia (refractory IDA), normalized after the H. pylori eradication
therapy and also the improvement of anemia without iron supplementation [11-13].
3.1. Routes of transmission
A number of studies propose environmental sources, such as animal and water exposure, as
potential forms of H. pylori infection. Also, a human-to-human transmission through oral-oral,
fecal-oral, or both has been described. H. pylori has been detected in saliva, vomitus, gastric
reflux, and feces [6, 8, 33, 34, 39-42].
3.1.1. Animals as potential source of H. pylori
Two epidemiological studies reported that the exposure to sheep was implicated in H. pylori
infection. Goodman et al. [35] described a higher risk of H. pylori infection, in the Colombian
Andes, in children who played with sheep. Dore et al. reported an association between a
prevalence of infection in 98% of Sardinian shepherds and the contact with sheep and
sheepdogs. In that study, the individuals had a significant increase of infection prevalence not
observed in their family members, with no regular contact with sheep (73%) or sheepdogs
(43%). A subsequent recovery of H. pylori in sheep milk led Dore to suggest that H. pylori may
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview80
be a commensal of sheep and thus the last ancestral host of H. pylori. The isolation of H.
pylori in the stomach of cats led Handt et al. to suggest that cats may also represent a reservoir
of the bacteria [27, 29, 43]. Rothenbacher et al. found that adults, who owned cats as children,
had a higher prevalence of H. pylori infection. Contradicting these studies were El-Zaatari et
al. who reported, in 25 stray cats, no infection by H. pylori. They found another strain,
Helicobacter heilmannii to be responsible for chronic gastritis in cats. Two seroepidemiological
studies in the United States, involving pet owners, failed to support the association of the
relationship between pet owners and an increased prevalence of H. pylori [32]. One large
population-based study in Canada, adjusted for social class, found no association between pet
ownership and peptic ulcer disease. With these results, a relation between cats and H. pylori
infection does not seem possible, and cats are not a health problem for cat owners [34].
3.1.2. Water transmission
H. pylori can survive for several days in milk and tap water in an infectious bacillary form. In
rivers, it can survive in a coccoid form for several months. Under physical or chemical stress,
H. pylori is capable of converting into a viable form. It is not known whether this coccoid form
can revert to its infectious form. Several studies support this form of transmission [34, 39, 40,
44]. In 1993, Westbloom detected H. pylori in the sewage water in Peru [6]. Hulten et al. showed
that in a population of Peruvian children, which consumed an internal source of water at home,
the likelihood of having infection with H. pylori was tripled [39]. In Colombia, children who
swam in rivers, streams, and pools and drank from a stream contaminated with sewage water
had a higher tendency of acquiring the infection. In South America, Hopkins et al. found, in
Chilean children who consumed uncooked vegetables contaminated with water containing
raw sewage, an increased prevalence of the infection [33-35].
3.1.3. Fecal-oral transmission
Some studies support the evidence of the transmission of H. pylori through its elimination in
feces after turnover of gastric mucosa. Thomas et al. in 1992 detected it in the feces of one adult
and 9 of 23 children living in a Gambian village, using the culture method. The isolation of H.
pylori from feces has been controversial. Parsonnet et al. [41] cultured the bacteria in feces, in
7 of 14 H. pylori-infected adults after cathartic-induced diarrhea. Mapstone et al. in 1993
detected H. pylori DNA by polymerase chain reaction (PCR). Some studies reported detection
of H. pylori by DNA, in feces, in 25–90% of H. pylori-infected patients [34]. In 1993, Hopkins et
al. observed that the consumption of fertilized vegetables with human feces was a risk factor
for acquiring H. pylori infection. The spreading through feces is supported by the occurrence
of infection in institutionalized people during gastroenteritis outbreaks [8, 34].
3.1.4. Oral-oral transmission
It is accepted that H. pylori infection acquisition occurs in early childhood by close interfamilial
contact. Many scientists report that oral-oral transmission is the most common form in
developed countries. This was supported by the high prevalence of H. pylori infection observed
in institutionalized people, within families, and in dentists. Megraud found, in Western Africa,
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a higher risk of H. pylori infection in children fed with premasticated foods by their parents
[34]. Parsonnet et al. [41] isolated H. pylori from saliva, vomitus, and cathartic stools in 16
healthy volunteers, infected adults, using culture and PCR methods. Ferguson et al. also
demonstrated by PCR, a low number of H. pylori from the saliva in one of the nine H. pylori-
positive subjects. By using soluble electrophoresis on polyacrylamide slab gels, restriction
endonuclease analysis, and Southern blot hybridization, they confirmed that the same strain
was isolated from both saliva and gastric biopsy [42]. In 1993, Mapstone detected H. Pylori in
the oral cavity, by culture, in one person. Majmudar et al. using PCR diagnosed H. pylori in
dental plaque [6, 8]. Cellini et al. reported the isolation of H. pylori from the dental plaque of
1 in 20 H. pylori-positive patients. Comparing the protein patterns and the restriction endo‐
nuclease pattern of the bacteria, those isolated from gastric biopsy and from dental plaque
showed to be identical [32]. Peach et al. found an association between H. pylori infection with
a high plaque score. However, studies conducted by other investigators did not find a
relationship between dentist visits, number of times that teeth were brushed, and periodontal
status. Doré-Davin et al. found no correlation between H. pylori infection, determined by PCR,
on saliva and dental plaque. They state that the transmission was done by gastro-esophageal
reflux or regurgitation of gastric contents [34, 41, 42].
4. Pathogenesis of H. pylori infection in extradigestive pathologies
It is known that the immunological response triggered by the bacteria is responsible for gastric
mucosa damage. Large amounts of pro-inflammatory substances, such as cytokines, eicosa‐
noids, and acute phase proteins, are released after H. pylori colonization [14-19]. Also, cross
mimicry between bacteria and host antigens may contribute to gastric mucosa damage [8, 22].
Although H. pylori gastric colonization induces histological changes in gastric mucosa, leading
to chronic gastritis in all infected people, most have no symptoms. The risk of developing
symptoms will depend on factors, such as the interaction between the host and the bacterium,
host genetic and immune response, diet and level of gastric acid. Host immune gene poly‐
morphisms and gastric acid secretion determine the bacterium’s ability to colonize a specific
gastric niche. Some bacteria strains are more virulent than others. The increase of pathogenicity
is related to the induction of morphological changes, vacuolation, and successive degeneration
of cells in vitro. The protein vacuolating cytotoxin VacA and the cytotoxin-associated gene
pathogenicity island-encoded protein CagA seem to be essential for the colonization and for
modulating the host’s immune system. The pathogen effects of H. pylori are related to chronic
inflammation, with the promotion of pro-inflammatory and anti-inflammatory mediators.
Host genetics polymorphisms can affect the expression levels of these mediators [8].
4.1. Pathogenesis of H. pylori in extradigestive disorders
The role of H. pylori in the pathogenesis of extradigestive disorders is based on (1) local
inflammation has systemic effects, (2) H. pylori infection is a chronic process that persists for
several decades, and (3) the persistent infection induces a chronic inflammatory and immune
response that can induce lesions locally and remote to the primary site of infection [14]. In
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addition to the above, several reports have revealed the role of H. pylori infection in hemato‐
logical problems [10, 16, 45]. Unexplained ID, IDA, and cITP are the most common problems
encountered in pediatric groups [11, 16]. Vitamin B12 (vit.B12) deficiency was the first
hematological disease associated to H. pylori infection and considered an elderly age group’s
disease. A study conducted by Rogers et al. for the evaluation of risk factors contributing to
low or marginal vitamin B12 concentration in Guatemalan school children revealed that
malabsorption conditions can interfere with vitamin uptake of the diet. A normal vitamin B12
status is expected despite a low intake because of this efficient enterohepatic circulation. An
additional hypo/achlorhydria produced by H. pylori infection can be the trigger to the devel‐
opment of cyanocobalamin deficiency in this young age group [46].
Gastric MALT lymphoma, also known as mucosa-associated lymphoid tissue (lymphoma),
is a low grade B-cell lymphoma described by Isaac and Wright in 1993 as an adult disease
and extremely rare in children. H. pylori stimulates the B and T lymphocytes of the stom‐
ach. B cells form clones, possibility by trissomia-3 mutations, and can become low-grade
MALT lymphoma. The H. pylori dependence is by-passed to H. pylori independence with
genetic  mutations  t(1:14)  with  a  transformation  to  high-grade  MALT  lymphoma,  not
documented in children [9, 47, 48].
The Scientific community has discussed and incorporated international consensus guidelines
for investigation and management of these hematological extragastric pathologies (IDA, cITP,
vitamin B12 deficiency, and MALT lymphoma) [5, 49-51]. No international consensus was
obtained for other hematological changes. However, autoimmune neutropenia was docu‐
mented in 2002 by Gupta et al. [52] with the report of a patient with a neutropenia (400/μl),
which normalized after H. pylori eradication. Papadaki et al. [53] in 2006, after evaluating 67
adult patients with chronic neutropenia and splenomegaly, found a higher prevalence of H.
pylori infection compared to healthy controls.
According to literature, other hematologic problems may be associated to H. pylori infection.
For example, leukemia in children, whose mothers are chronic carriers of H. pylori, increased
risk of gastric bleeding in children with acute leukemia, H. pylori infected, and in patients with
genetic diseases prone to hemorrhage (Hemophilia A and B and thrombasthenia) [15, 16].
5. Iron deficiency anemia
The World Health Organization (WHO) estimates that approximately 50% of all anemic
patients have a diagnosis of IDA [1, 30, 31, 50, 51, 54]. In infancy, IDA is associated to abnormal
mental and motor development. In developed countries, low intake, increased host require‐
ments to supply the physiological needs for normal development, dietary errors, and blood
loss are the most frequent causes of IDA in children [15, 45]. The evidence to support a causal
association between H. pylori infection and ID or IDA is based on epidemiological studies and
clinical trials. The first clinical case was described by Becker in 1991, in a 15-year-old girl, H.
pylori positive, whose clinical presentation was a chronic active hemorrhagic gastritis, without
gastrointestinal symptoms. In 1993, Dufour et al. reported a 7-year-old child without evidence
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of hemorrhage or clinical symptoms, with refractory IDA to oral iron therapy. The investiga‐
tion revealed an H. pylori-positive patient. High endoscopy showed chronic antral gastritis and
H. pylori eradication reversed the anemia [55]. These case reports were followed by other
studies that have documented an association between H. pylori infection and unexplained or
refractory IDA with reversal of anemia and a normalization of iron stores after successful H.
pylori eradication, with or without iron supplementation [10, 45]. A recurrent ID or an
inadequate response to oral iron therapy implies searching for H. pylori infection. All guide‐
lines and international consensus support that H. pylori should be sought and eradicated in ID
cases [5, 49, 50, 56].
5.1. Pathophysiology of iron deficiency by H. pylori
The intrinsic biological mechanisms by which H. pylori infection induces ID, IDA, or refractory
IDA are not fully understood. However, several pathways are involved: occult blood loss,
changes in gastric physiology as the result of chronic gastric inflammation and of low gastric
acidity and ascorbate, as well as mechanisms used by the bacteria for its growth [11-13, 55].
5.1.1. Occult blood loss
Chronic gastrointestinal blood loss is one of the supposed intrinsic mechanisms. However,
most case series of H. pylori patients with anemia and chronic gastritis do not reveal gastric
bleeding lesions at the time of endoscopy, and positive occult fecal blood tests are not always
present [45, 57]. The occult fecal blood test is a qualitative and highly accurate (98%) form of
detecting human fecal hemoglobin, based on a flow chromatographic immunoassay, it is a
diagnostic approach for the evaluation of gastrodigestive pathology of detecting human fecal
hemoglobin, based on a flow chromatographic immunoassay [58]. A literature review by Susan
Owens et al. about gastrointestinal bleeding in children, considered the H. pylori infection in
children with hemorrhagic hereditary disorders, such as hemophilia A and B as a risk factor
for severe hemorrhage [16]. Also, Campuzano-Maya mentioned that an increased risk of
hemorrhage is observed in patients with acute leukemia infected with H. pylori, which have a
greater risk of gastrointestinal hemorrhage during treatment compared to uninfected patients.
This risk is reduced if a screening and eradication therapy, is offered to all leucemia patients
upon starting leucemia treatment if they are infected [16] Therefore, in patients with potentially
hemorrhagic genetic diseases, such as hemophilias (A and B) and Von Willebrand disease, H.
pylori infection should be considered as an important cause of upper gastrointestinal bleeding.
The authors recommend a stool antigen test as a new and non-invasive screening test for
diagnosing H. pylori infection in all patients with hereditary hemorrhagic disorders [16].
5.1.2. Changes in gastric physiology: gastric inflammation and chronic disease anemia
Gastric mucosal inflammation is an invariable finding in H. pylori-infected patients and
represents the host’s immune response to the bacteria [59]. Several mechanisms have been
postulated: (a) directed mucosal injury enhancing permeability and the antigen exposure; (b)
adherence of bacteria to the gastric mucosal, accompanied by microvilli loss, irregularity of
luminal border, edema and vacuolation; (c) toxic effect of the bacteria on epithelial cells with
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a gastric epithelial degeneration, access to underlying mucosa, stimulating host non-specific
and specific responses involving several cytokines’ liberation [59].
5.1.2.1. Directed mucosal injury
Two instances should be considered in the invasion of H. pylori in gastric mucosal. In the first,
H. pylori colonizes, living in the mucus layer in proximity to the epithelial surface. This
interaction leads to epithelial cell damage and liberation of pro-inflammatory cytokines [8, [59].
5.1.2.2. Adherence of bacteria to the gastric mucosal
After the initial colonization, H. pylori migrates to the mucosa with stimulation of immune
responses. All H. pylori strains have the gene for vacuolation cytotoxin (VacA), but only 50%
produce the VacA protein, capable of vacuolation eukaryotic cells and prone to insertion into
the membranes of endosomal vesicles forming pores with chloride channel activity. This alters
the anions’ composition within the endosomes, which leads to osmotic swelling, cellular death
and apoptosis, and a more severe degree of inflammation and peptic ulceration [59].
5.1.2.3. Toxic effect
Several enzymes produced by H. pylori may contribute to changes in gastric mucosa permea‐
bility. H. pylori is one of the most powerful urea-splitting organisms. Splitting urea leads to the
release of nitrogen and ammonia, increasing the pH of the gastric antrum, one of the mecha‐
nisms that protects the bacteria from the gastric acidity and has a toxic effect on the mucosa.
Bacterial phospholipases can destroy gastric mucosa phospholipids, and acetaldehyde
dehydrogenase production may have also a toxic mucosal effect [59].
5.1.3. Recruitment of inflammatory chemokines and inflammatory cells
H. pylori is a non-invasive bacterium. However, after the initial phase of the colonization, a
dense infiltration of granulocytes begins and it is followed, in the chronic phase, by a pre‐
dominant infiltration of plasma cells and lymphocytes. It seems that signal transduction
pathways must exist in order to induce the recruitment and immigration of inflammatory cells
to the gastric mucosa. Additionally, soluble bacterial products may initiate the inflammatory
cascade [17, 60]. Gastric H. pylori infection is associated to the epithelium release of several
chemokines [60, 61]. Each chemokine is involved in the recruitment and activation of a specific
immune cell. Potential chemoattractants of the CXC chemokine family, IL-8, GRO-α, and
epithelial cell–derived neutrophil-activating protein 78 (ENA-78), are involved in the recruit‐
ment of neutrophils. Members of the C-C family (RANTES, MIP- 1α) have specificity for
monocyte and lymphocyte recruitment. IL 8 expression has been detected in epithelial cells of
antral biopsy and in the supernatant of antral biopsy samples in H. pylori-infected patients [59,
60]. H. pylori induces gastric epithelial cells to increase transcription and secretion of IL 8. TNF-
α has an effect on leukocyte activation, and IL7 has a regulating role on lymphocytes B and T
[59]. Studies state that cytokine levels, with a pro-inflammatory effect, such as IL-6, IL-8, and
TNF-α are higher in H. pylori-positive patients than in H. pylori negative [49]. Among these,
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IL-6 is the most important pro-inflammatory cytokine inductor of the hepcidin gene tran‐
scription through STAT3 (signal transducer and activator of transcription 3) [61, 62]. Hepcidin
is a small peptide hormone primarily expressed in hepatocytes as a propeptide precursor.
Prohepcidin is processed to a bioactive molecule of 25 amino acids, the hepcidin that is secreted
into the blood stream and eliminated in urine. Hepcidin is the most important regulator of
iron homeostasis [63, 64]. The expression of hepcidin is regulated on a transcriptional level by
two principal pathways. The first is the activation of STAT 3. Upon activation, these proteins
are transferred to the nucleus where they activate transcription of the hepcidin gene, binding
to a sequence of DNA. The second is transcription control dependent on the BMP/Smad
pathway, which involves Smad proteins and bone morphogenetic proteins (BMPs). Factors
that can affect the expression of hepcidin are iron, anemia, hypoxia, and inflammation [61-68].
Hepcidin is a negative regulator of a transmembrane protein, ferroportin, which is expressed
on the surface of all cells that release iron in circulation: enterocytes, macrophages, hepatocytes,
and placental cells. Hepcidin regulates ferroportin at a translational level [67]. Under inflam‐
matory conditions, hepcidin reacts as an acute reagent phase, increasing its expression, binding
to ferroportin for tyrosine phosphorylation and also the internalization and ubiquitin-
mediated degradation in lysosomes, resulting in hypoferremia and no iron availability for
erythropoiesis, the hallmark of inflammatory anemia. In 1932, Locke et al. observed that
infection was associated with low serum iron levels [63, 64]. This finding was corroborated by
Cartwright and Wintrobe with the demonstration that anemia associated with infection was
not different from anemia of inflammation, resulting in a pathology known as anemia of
inflammation or chronic disease anemia [63, 68]. On the other hand, H. pylori can subvert
human iron to benefit itself instead of the host, and recently hepcidin has been identified in
the parietal cells of H. pylori-infected patients with an upregulated gastric hepcidin and a
consequent downregulation of ferroportin [63, 67, 69].
5.1.4. Hypochlorhydria
Iron absorption takes place in the small intestine in accordance with the metabolic demands
that reflect the amount of iron stored for erythropoiesis. Haem iron refers to the pool of iron
incorporated in the protoporfirin ring. Its absorption is more effective than non-haem iron and
the mechanisms for absorption are different. HCP 1 (haem carrier protein) is a protein capable
of the transmembrane transport of haem into the lumen of enterocytes to be catabolized by the
microsomal enzyme haem oxygenase. The non-haem iron (Fe3+) is not soluble and is the most
prevalent alimentary iron. Its absorption is dependent on endogenous factors related to its
reduction to a soluble iron form (Fe2+), such as duodenal cytochrome b reductase, and the
ascorbic acid released by gastric cells [70]. Gastric acidity increases the absorption of Fe 3+ in
two ways: (1) the high concentration of hydrogen ions at acidic pH (pH 3 = 1 mM H+) leads to
an efficient competition for metal iron in bindings sites, on dietary components; (2) mecha‐
nisms related with the release of soluble ferric ions only in acidic pH (pH<4) [71]. In 1905, John
Edkins postulated gastrin as the hormone regulator for gastric acid secretion [72]. Sarker et al.
[65] revealed that the basal and stimulated gastric acid was greatly reduced in H. pylori-infected
children compared to non-infected [10, 16, 71]]. The same author revealed, in a study with H.
pylori-infected children of Bangladesh, that this infection was associated to impaired gastric
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secretion. After H. pylori eradication, improved gastric secretion and hemoglobin concentra‐
tion was observed but no influence on iron absorption was verified. Other possible mechanism
such as competition for oral iron and inflammatory disease was considered a possibility. A
study performed by Harris in 105 children, 33 H. pylori positive and 72 H. pylori negative, found
a significantly higher percentage of H. pylori-infected children with a gastric juice pH above
4.0 (6/33, 18%) compared to H. pylori-negative children (6/10, 60%) [70]. While hypochlorhydria
and acute H. pylori infection in adults is well documented, the mechanisms inducting hypo‐
chlorhydria in children are not well understood [8, 10, 16, 70]. H. pylori can induce hypochlo‐
rhydria through increased gastric IL-1β and TNF-α, both in adults and in children, which
inhibits acid gastric secretion, induces parietal apoptosis, and decreases enterochromafin-like
cell histamine release [10, 70]. Capurso et al. [67] demonstrated that H. pylori-infected IDA
patients, with involvement of corporal gastric mucosa, had an important decrease of gastric
acidity (pH>4) with higher intragastric pH and high serum gastrin levels. Serum gastrin is an
indirect marker of atrophic gastritis [11, 12, 73]. As described by Hartmann et al., iron malab‐
sorption can be confirmed by an oral iron challenge. In fast, 2 mg of iron sulfate is adminis‐
trated, and the dosing of iron serum is done before ingestion and then after the first, second,
and third hour. It is considered poor absorption when at the first hour the iron serum level is
<100 μg/ml (Figure 1) [74]. Recently, H. pylori has been implicated in unexplained refractory
IDA to oral iron treatment. This refractoriness may be defined as a failure of the hemoglobin
increase at least 1 g/dL after 2 months of treatment [13]. Celiac disease is the most known
pathology related with malabsorption conditions. AAG, manifested as hypergastrinemia, with
strongly positive antiparietal cell antibodies, was for many years considered a disease of older
people and vitamin B12 deficiency the only possible presentation. The age, gender, and
severity of the disease are determinants for the presentation in microcytic or macrocytic anemia
[11-13]. Although atrophic gastritis may impair both vitamin B12 and iron, the increase in the
iron demands for the observed growth in children and adolescents as well as the menstrual
blood loss in pubescent females, make IDA easier to develop. H. pylori can trigger AAG by a
molecular mimicry between the bacteria and H+ K+-ATPase. In children, a refractory IDA
without evidence of gastrointestinal blood loss implies in first line, non-invasive tests for Celiac
disease (anti-endomysial antibodies IgG and IgA), AAG (serum gastrin in fasting and anti-
parietal cells antibodies), and H. pylori infection (H. pylori IgG antibodies followed by urease
breath test) [11-13]. IDA in the AAG context was described by Faber in 1909 and then com‐
pletely ignored and forgotten. The role of H. pylori in AAG development is not consensual
because of the high prevalence of this bacteria in the world population. However, eradication
of H. pylori in this context is accompanied by a normalization of hemoglobin, iron stores, and
gastrin levels [13, 16, 75].
5.1.5. Low ascorbic acid level
Vitamin C is an acidic molecule with strong reducing activity. Ascorbic acid (AA) is the
reduced form of vitamin C. It is a potent antioxidant, a protector against gastric carcinogenesis,
neutralizing nitrite-derived mutagens. Vitamin C is essentially absorbed and secreted in the
antral mucosa. It has two major redox forms: AA and dehydroascorbic acid (DHA), the reduced
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and oxidized forms, respectively, and interconvertible. Within the cell, DHA is rapidly
converted to AA by the specific enzyme systems, such as DHA reductase, glutaredoxins, and
protein disulfide isomerase, in the presence of glutathione or other thiols as electron donors
[76, 77]. Unlike AA, DHA is relatively unstable and undergoes rapid, spontaneous, and
irreversible hydrolysis particularly at pH>4. Annibale et al. [73] demonstrated that gastric juice
and ascorbate content are negatively affected by H. pylori infection and a normalization of
ascorbate and gastric pH was obtained with eradication therapy [11-13, 78]. In H. pylori–
infected children, a reduced gastric juice ascorbic acid concentration was found, and this effect
was more evident in patients with CagA-positive strains [10, 30, 66, 71, 77]. A Korean study
with the involvement of 452 patients (228 boys, 224 girls) aged 1–15 years revealed a negative
correlation between gastric vitamin C level, H. pylori concentration, and the degree of active
inflammation in antral mucosa. In this group, data showed that vitamin C levels in whole
blood, plasma and gastric juice as well as the intragastric pH were closely related to the severity
of the H. pylori infection and the histological changes in the stomach. These findings suggest
that vitamin C may play a role in determining infection and progression [76, 79]. Studies have
demonstrated that H. pylori produces gastric vitamin C reduction, promoting its degradation
to DHA, a metabolite that may be oxidized at an irreversible form. This is unstable at high pH
values, and thus hypochlorhydria reduces the bioavailability of this vitamin, essential for iron
reduction to ferrous form, which forms an absorbable molecular complex with ferric iron,
insoluble at pH>5 [10, 30, 45, 80]. Baysoy et al. documented a greater decrease in gastric juice
ascorbate in H. pylori-infected patients with CagA-positive strains compared to those with
CagA-negative strains [10, 45, 70, 71]. However, in this group, no association among CagA-
positive strains and IDA has been found.
Figure 1. Oral iron challenge study. At the time, 0.2 mg/kg of elemental iron as ferrous sulfate was given. The expected
normal response range, derived from 24 iron-deficient children but with normal absorption after given an oral dose of
1 mg /kg of elemental iron. Adapted with permission from Hartman and Barker [74]. Copyright ©1996.
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5.1.6. Utilization/sequestering iron by H. pylori
H. pylori, like other pathogenic bacteria, requires iron as a growth factor [8]. However, H.
pylori does not produce siderophores capable of extracting iron from proteins. Potential iron
sources  for  H.  pylori  are  transferrin,  lactoferrin,  ferritin,  hemosiderin,  heme,  and  iron-
containing enzymes [3, 81]. Lactoferrin is a source of iron for H. pylori in gastric mucosa.
Choe et al. reported an abnormal elevated lactoferrin level in the stomachs of 101 adoles‐
cents with unexplained epigastric pain, ID, and H. pylori positive [10, 45, 82, 83]. A concord‐
ance was obtained with studies published by Dogan et al. [83] related to the gastric issues of
61 children with recurrent abdominal pain, 45 of which were H. pylori positive. It is known
that  lactoferrin captures iron from transferrin.  H. pylori  has a  highly specific  lactoferrin-
binding protein. Thus, iron bound to lactoferrin is directed to H. pylori. The bacteria have a
19 KDa iron-binding protein that resembles ferritin, storing the iron, and making it unavail‐
able for erythropoiesis [8, 67].
5.1.7. Inhibitor effect on duodenal mucosa cells
Duodenal mucosa cells are responsible for iron absorption. H. pylori can exert an inhibitor effect
on the duodenal mucosa [8, 10].
5.2. Diagnosis
Symptoms of H. pylori infection in children are non-specific and can include: abdominal pain
after meals, unexplained anorexia, nausea, recurrent vomiting, hematemesis, and IDA. These
symptoms are considered to be of low predictive value. A meta-analysis of 45 studies con‐
cluded that H. pylori infection is not associated with abdominal pain. Therefore, an H. pylori
infection diagnosing test for abdominal pain is not recommended as the first step of investi‐
gation [5, 49, 50, 56, 84]. In contrary, in a briefing for the European Gastroenterology Review,
Mafertheiner et al. recommend that in children with a family history of peptic ulcer and gastric
cancer, a recurrent abdominal pain should be subjected to testing for H. pylori after exclusion
of other causes [49]. Based on the development of a chronic pangastritis with a consequent
achlorhydria and reduced ascorbic acid, interference with iron absorption, occult blood loss
by erosive gastritis or peptic ulcers, competition for the alimentary iron and sequestering by
the bacteria, it seems reasonable to recommend testing for H. pylori infection on unexplained
ID or IDA. Evidence-based guidelines from European Society for Pediatrics, Gastroenterology,
Hepatology and Nutrition (ESPGHAN) and the Group of the North American Society for
Pediatric Gastroenterology (NASPGHAN) in 2011 for IDA in context of H. pylori infection in
children are in accordance with the Canadian Group Consensus Conference in 1999 [5, 49,
50]. They recommend considering diagnostic tests in children with refractory IDA, after the
exclusion of other causes and in children with first-degree relatives with gastric cancer. In 2007,
the American College of Gastroenterology, in their guidelines for the management of H.
pylori infection, questioned this conclusion. Large studies from North America have reported
that H. pylori infection was an independent risk factor for IDA in 688 school-aged children from
Alaska and 7462 children, adolescents, and adults, all from the United States. A recent
unblended study of 219 H. pylori-infected children, aged between 7 and 11 years, also from
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Alaska, with pretreatment ID, found no difference in the likelihood of iron deficiency or anemia
at 2 months or 14 months following a 6-week course of oral iron and antibiotics or no antibiotics.
These data points support an association between H. pylori infection and IDA, but do not prove
cause and effect. On the other hand, most studies refer to a relationship between H. pylori
infection and IDA as well as a normalization with eradication therapy [11-13, 16, 49]. Antibody
tests for H. pylori infection using whole blood, serum, and saliva are not recommended because
of the low prevalence of H. pylori-related diseases in children and low specificity and sensitivity
of the testes [51, 84].
6. Idiopathic thrombocytopenia purpura (ITP)
Immune thrombocytopenic purpura (ITP) is an autoimmune hemorrhagic disease, character‐
ized by isolated thrombocytopenia, which affects nearly 1:25000 children per year [85-87]. ITP
can present itself as an acute, self-limiting condition or a chronic process. Persistent thrombo‐
cytopenia, for longer than 6 months, may be present in about 20% of children [88-91]. A
controversial issue in children is the designation “Chronic immune thrombocytopenia (cITP),”
because about a third of children with ITP spontaneously cure from 6 months to 1 year later
[87-89]. The International Childhood ITP Study Group recommends that 12 months must be
the cutoff point for defining cITP [88, 90]. ITP is characterized by a premature destruction of
platelets. Autoantibodies interact with the glycoprotein membrane on surface platelets (GIIb/
IIIa or GIb), resulting in accelerated platelet destruction and clearance by mononuclear
phagocytes [86, 91-93]. Increased megakaryocyte number in bone marrow is the marker of ITP
in childhood [91]. However, studies performed in 1980 revealed that in two thirds of adults
the expected increase of megakaryocyte production was not observed. Most of ITP had normal
or depressed platelets turnover [87]. Chang et al. evaluated the effect of plasma, from child‐
hood patients with ITP (44 with an acute form and 9 with chronic ITP), on induced throm‐
boietin production of megakaryocytes in liquid culture. They reported that plasma from
pediatric patients with ITP suppressed in vitro megakaryocyte production. They cultured cord
blood cells as a source of CD34+ cells, which is a thrombopoietic growth factor, and plasma
from control subjects or, children with ITP. After 8 days of culture, nearly 16% of cells were
megakaryocytes. The effect of plasma in three groups was compared: control plasma, antibody
ITP plasma (anti-GPIb, anti-GPIIIa, or both). They observed that in cultures with anti-GPIb
antibodies the number of megakaryocytes were strongly reduced but this did not occur in ITP
plasma negative antibody or in ITP plasma with only anti-GPIIb-IIIa antibody [93, 94].
Recently, thrombocyte kinetic studies have been carried out and autoantibodies affecting the
megakaryocytes production in the bone marrow were observed [87, 91, 93, 95]. Also, studies
using electronic microscopy showed 50–75% of ITP megakaryocytes damaged and in some
cases attached by monocytes [96]. In most cases, ITP in childhood is triggered by a previous
viral disease or a vaccination [87, 90]. HIV, hepatitis C, measles, cytomegalovirus, varicella,
pertussis, and parvovirus can all be found in this context [95, 97]. After a benign viral infection,
a predominant proinflammatory state may trigger ITP. Both proinflammatory cytokines and
T-cells persist, creating a permissive environment for the emergence of autoantibodies that
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bind to platelet membrane antigens [91, 93]. Zehnder et al. highlighted an increased expression
of gamma interferon-dependent genes in early states of ITP, supporting a proinflammatory or
TH1 profile [91, 95]. ITP affects both adults and children. However, the natural course of ITP
in children is different from adults. Spontaneous recovery occurs in one third of the pediatric
patients, months or years after the diagnosis. Several studies in adults reported improvement
in platelet counts after H. pylori eradication therapy [91, 98, 99]. Few studies exist related to
children and the ones that do exist have contradictory findings. In a study developed in
Taiwan, Jaing et al. evaluated 22 cITP children H. pylori infected, after one or two courses of
eradication therapy. They found that 55.6% of patients experienced total or partial remission
after an average of 16 months. In the Netherlands, a study carried out by Niefjes et al. evaluated
47 children with cITP, 3 of them H. pylori infected. They were treated with a 2-week course of
triple therapy and after 6 months all of them acquired complete remission. In an Iranian study
by Hamidieh et al., 31 cITP children were evaluated. Four of them were H. pylori infected and
treated with 2 weeks of triple therapy. None of them acquired partial or complete remission.
In Italy, Bisogno et al. evaluated 25 children with cITP. Nine of them were H. pylori infected
and treated with 1–2 courses of 2 weeks of triple therapy. After 6 months, three patients had
an increase in platelet counts and one had remission. This author also reported complete
remission in 16 H. pylori-negative patients. The follow-up of the last 10 H. pylori-negative
patients presented a platelet count above 50×109 without any treatment [10, 45]. Several studies
revealed a widely variable prevalence among different populations according to the countries’
epidemiology. In Finnish populations, H. pylori was not found in any of the 17 pediatric
patients [100]. Turkish children showed H. pylori infection in 11 of 35 children (31%). Japan
reported a prevalence of H. pylori infection in 2 of 10 (2%). Chinese children from northern
Taiwan showed the presence of infection in 9 of 22 (41%) children. The response to the
eradication therapy was not uniform [101, 102]. H. pylori has been implicated in the pathogen‐
esis of several autoimmune diseases [90, 95, 97]. ITP is a typical organ-specific autoimmune
disease. In adult patients with ITP associated to H. pylori infection, eradication therapy has
been associated to an increase in platelet count. The Maastricht Consensus in Florence in 2012
approved, in adults with ITP and H. pylori infection, a similar approach to the one used in those
with IDA associated to H. pylori infection. In the pediatric age group with cITP, diagnosis tests
for identification of H. pylori infection, such as 13C-urea breath test, stool antigen test, or IgG
serology, are not recommended. According to the guidelines described by Peter Mafertheiner,
the recommendation for H. pylori eradication therapy in diseases like idiopathic thrombocy‐
topenia was approved for adults [49].
Several mechanisms by which H. pylori may be associated to ITP have been proposed.
6.1. Possible mechanisms by which H. pylori may be related to ITP
6.1.1. Molecular mimicry
One theory is that cross-reactive antibodies produce reactions with H. pylori components and
platelet glycoprotein through a molecular mimicry [90, 98]. Michael et al. tested platelet eluates
derived from H. pylori-infected patients and found that platelet eluates with the capacity to react
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with GPIIb/IIIa or GPIb failed to recognize any H. pylori antigens [90]. Recently, it was report‐
ed that monoclonal antibodies generated against H. pylori urease B react with GPIIb/IIIa, on
platelet surface, suggesting that cross-reacting antibodies may be present in ITP patients [90].
6.1.2. Binding between H. pylori to von Willebrand factor/induction of platelet aggregation and
apoptosis
Many diseases associated to platelet aggregation have been described as related to H. pylori
infection [90, 101, 103]. Myocardial infarction, coronary heart disease, and stroke are examples
of this prothrombotic condition. H. pylori may trigger both thrombotic thrombocytopenic
purpura (TTP) and ITP by the induction of the interaction among platelets and von Willebrand
factor (vWF). Studies suggested that vWF is essential for platelet aggregation induced by H.
pylori [90, 103]. The mechanisms that lead to platelet aggregation in this infection are well not
understood. Byrne et al. revealed that not all H. pylori strains can promote platelet aggregation
[96]. H. pylori strain 60190 (ATCC49503) induces platelet aggregation through interaction
between H. pylori, its antibody, platelet receptor FcγRIIA (CD32), and vWF and its glycoprotein
receptor (GP)Ib/IX, produced in endothelium and in megakaryocytes (α2 granules) [103]. H.
pylori virulence factors, the Cag pathogenicity island (CagA), and the VacA are responsible for
ITP, but are not related as a cause of platelet aggregation. Platelet apoptosis has also been
described. H. pylori promotes platelet aggregates and platelet apoptosis, which may explain
the decrease in platelet counts in TTP and ITP cases [101, 103]. This may also explain the
remission observed with the eradication therapy in adults. In childhood, contradictory
findings with discrepancy in the response to eradication therapy suggest that in most pediatric
cases ITP is primary, not secondary to H. pylori infection [16, 89].
6.1.3. Modulation in the monocyte/macrophage function
Change in the balance of the Fcγ receptor, related to the activation of monocytes, leads to
increased monocyte function with phagocytosis and autoreactivity of B and T lymphocytes
[16]. H. pylori can be linked to autoantibodies produced by B lymphocytes and to an over
reactivation of innate and acquired immune response against platelets [16, 85, 89]. CD4+ T
helper cells regulate B cells, which release antithrombocyte antibodies [92, 95]. An upregula‐
tion of the genes involved in cell-related toxicity (granzime, perforin) (CD3+ CD8+ T cell) is
observed [92, 104].
6.1.4. Non-specific activation of immune system
The major antigenic component for antibody production against H. pylori is urease. Urease
antibodies initiate autoimmune responses through autoantibodies produced by the activation
of B1 cells [102].
6.2. Genetic characteristics of the patients
Recently, the role of genetic factors has emerged, indicating that H. pylori patients have a lower
frequency of DRB1*03 and a higher frequency of DRB1*11, DRB1*14, and DQB1*03 compared
to H. pylori-negative patients [1, 10, 90, 101].
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Based on the previously mentioned studies and mechanisms described, which lead to ITP in
H. pylori patients, as well as the discrepancy in the response to the triple therapy in pediatric
cases, to treat or not to treat H. pylori-infected children continues to be an unsolved question
[5, 49-51].
7. MALT lymphoma
For the first time, in 1983, Isaacson and Wright introduced the concept of mucosa-associated
lymphoid tissue (MALT), a marginal, extranodal, indolent B-cell non-Hodgkin lymphoma
[105, 106]. Predominantly found in females over the age of 50, it is quite rare in childhood. In
prospective, multicenter NHL-BFM treatment studies performed since 1986, composed of 2703
children, only in 4 (0.1%) MALT lymphoma was found. H. pylori infection was documented in
two out of four of these patients [106, 107]. The clinical pathological manifestation of extranodal
B cell lymphoma is similar to that presented in the MALT. MALT is a system composed of
small concentrations of lymphoid tissue, containing about half the lymphocytes of the immune
system [106]. Situated along the surfaces of all mucosa tissues, its principal function is to
produce IgA against specific antigens on the mucosal surfaces, TH2-dependent reactions, and
TH1 cytotoxic T-cell–mediated reactions, thus resulting in immune tolerance. Gut-associated
lymphoid tissue (GALT), nasopharynx lymphoid tissue (NALT), and bronchus-lymphoid
tissue are the most well-known examples. Also described are conjunctiva-associated lymphoid
tissue (CALT), lacrimal duct–associated lymphoid tissue (LDALT), larynx-associated lym‐
phoid tissue (LALT), and salivary duct–associated lymphoid tissue (DALT) [105-109].
Although MALT sites are separate, they are functionally connected in what is known as the
“common mucosal immune system”. In other words, the antigen presentation and B-cell
activation at one site can result in IgA secretion at another site in a different organ. MALT
tissue contains B and T cells, as well as plasma cells and macrophages. The B-cell component
(MALT) is found in Peyer’s patches, plasma cells of the lamina propria, and in the B-cell
compartment of the mesenteric ganglia. Gastric MALT lymphoma is a clear example of
lymphoid malignancy associated to chronic inflammation [105]. It can occur in the context of
chronic inflammation caused by some infectious agents, such as H. pylori (gastric lymphoma),
Chlamydia psitacii (ocular adnexal lymphoma), and Borrelia burgdorferi (cutaneous lymphoma)
[105]. MALT lymphomas arise in extranodal sites, frequently found in the stomach, lungs,
ocular adnexa, and thyroid as well as a small percentage in the small intestine [105, 108, 110].
In 1991, Wotherspoon et al. demonstrated, for the first time, that primary gastric lymphoma
was associated to H. pylori infection. Later, in 1993, the same author documented regression
of low-grade B-cell gastric lymphoma of MALT in five of six H. pylori-infected patients after
eradication [9, 110, 111]. Two types of MALT lymphoma have been identified: “native MALT
type” corresponding to lymphoid tissue present in the gut and “acquired MALT type”
developed in response to infectious events, such as H. pylori infection or autoimmune diseases
(Sjogren’s syndrome or Hashimoto thyroiditis). The histological feature of MALT lymphoma
is an infiltration of the marginal zone and diffusion into surrounding tissues, as well as the
presence of lymphoepithelial lesions formed by lymphoma cells in individual mucosal glands
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or epithelial structures. MALT lymphoma cells have the same cytological and immunophe‐
notype features (CD20+, CD21+ CD35+, IgM+, and IgD−) found in marginal zone B cells.
Although gastric MALT lymphoma has an indolent course, rarely it can progress to aggressive
high-grade tumors (extra-nodal large B cell lymphoma—eDLBCL) and, consequently, a drop
in the survival rate from 90 to 40 %, respectively [105].
7.1. Pathogenesis and H. pylori
Gastric MALT lymphoma results from a multistage process that begins with the H. pylori
infection and consequent recruitment of B and T cells [105, 112, 113]. The decrease in gastric
acidity  caused by the  urease  secretion triggers  the  lymphocyte  infiltration and thus  the
establishment of MALT. B-cells are stimulated by H. pylori T-specific cells, acquires genetic
abnormalities forming clones,  possibly by trisomy 3,  becoming H. pylori-dependent low-
grade lymphoma [112,  114].  It  has  been demonstrated that  lymphatic  follicles,  normally
absent in the gastric mucosa, can appear, and consequently, configure the MALT after an
inflammatory process [47]. H. pylori  virulence factors seem to be crucial for the develop‐
ment of gastric lymphoma. CagA-positive strains are frequently related to a more aggres‐
sive  lymphoma (eDLBCL)  [115].  H. pylori  can translocate  the  CagA protein  into  B-cells,
inducing extracellular signal-regulated kinase activation and promoting upregulation of Bcl-2
expression, resulting in the inhibition of apoptosis. Otherwise, H. pylori can induce genetic
mutation leading to the transformation of a normal B-cell to a malignant clone. The most
frequent  genetic  mutations  detected  are  t(11;18)(q21;q21),  t(1;14)(p22;q32),  and  t(14;18)
(q32;q21)  involved in  the  activation of  nuclear  factor-κB (NF-κB),  which plays  a  role  in
immunity, inflammation, and apoptosis [47, 113]. It has been found that positive CagA strains
were higher in patients with t(11;18)(q21;q21) compared to those without such transloca‐
tion (93.3 vs. 51%; P=0.01) [47, 114]. The transformation of low grade to high-grade lympho‐
ma is rare in children, but it is documented in adults [107]. Normally, MALT lymphoma is
a very indolent disease, localized for long periods of time. Systemic dissemination occurs in
a  few  cases.  In  a  large  multicenter  study  of  93  patients  with  low-grade  gastric  MALT
lymphoma in southern Switzerland and northern Italy, 49 H. pylori-infected patients with
stage I of the disease. Eradication therapy was given in 97% of patients, and histological
regression of MALT lymphoma was acquired in 67% of patients [114, 115]. The median time
to achieve histological regression was 5 months (range 3–18 months). International guide‐
lines recommend H. pylori eradication therapy in MALT lymphoma [5, 49, 50].
8. Diagnostic tests for H. pylori
Published consensus developed guidelines for the management of H. pylori infection in
children. In 2000, ESPGHAN, and after NASPGHAN, published recommendations for H.
pylori infection treatment [49, 51]. In 2004, the Canadian Helicobacter Study Group included
consensus about how to approach H. pylori infection in children [5].
About testing H. pylori infection, questions must be asked in this age group:
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Who should be tested? What tests should be used? Testing for H. pylori should be performed
if a positive result is expected. A test and treat strategy is not recommended in children. The
methods of diagnostic tests for H. pylori infection may be divided into two categories: invasive
and non-invasive tests [5, 49-51].
8.1. Invasive tests
Invasive tests require a gastric endoscopy and a biopsy with culture for detecting H. pylori [116,
117]. They are the only tests considered to be 100% specific. The hematoxylin–eosin (HE) stain
usually shows H. pylori strains [114, 118]. Nevertheless, when the results are inconclusive, there
are at least two different stain techniques to be used on biopsied tissue: HE to evaluate
inflammatory cells and Giemsa or Genta stain to detect H. pylori. Although the Genta stain due
to a combination between a silver stain, HE and Alcian blue can visualize both inflammatory
cells and H. pylori strain with higher accuracy, this formulation is technically complex. In
contrast, the Giemsa stain is technically simple, highly sensitive, and inexpensive [117, 119].
8.1.1. Rapid urease test (RUT)
RUT identifies H. pylori through urease activity of the bacteria in gastric mucosa [120, 121].
Gastric biopsies are obtained and placed into an agar gel on a reaction contained urea, a buffer,
and a pH-sensitive indicator. In presence of H. pylori, urea is metabolized to ammonia and
bicarbonate leading to an increase of gastric pH, with changing in color [8, 117, 118]. The low
cost, the simplicity, and rapid results make this test practical and effective, as long as the patient
has not taken proton pump inhibitors or antibiotics. Medication that reduces the density of
bacteria can decrease the sensitivity of the RUT up to 25%. Therefore, proton pumps and
antibiotics must be not taken 1–2 weeks before the procedure [5, 49-51]..
8.1.2. Histology
Histology is considered a standard method for detecting H. pylori infection. The sensitivity
and specificity vary according to the site, number, and size of the biopsies, and also the
experience of the pathologist [82, 117, 118]. False results can be obtained with a low densi‐
ty of bacteria. In these cases, multiple biopsies are needed. The majority of gastroenterolo‐
gists obtained only biopsies of the antrum [122]. Recent studies revealed that the addition of
corpus biopsies to antral biopsies increase the probability of H. pylori  identification in all
infected patients [50, 51, 117, 118].
8.1.3. Cultures
Cultures method has high specificity for the diagnosis of H. pylori infection, normally unnec‐
essary for routine the diagnosis of H. pylori. The principal indication is testing for antimicrobial
sensitivity in order to choose the appropriate antibiotic. Cultures are expensive and not as
sensitive as RUT or histology and not available in many clinical laboratories [119, 120].
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8.1.4. Polymerase chain reaction
PCR is a DNA amplification that uses the rapid production of a target DNA sequence to
identify H. pylori. It is capable of identifying H. pylori strains in biopsies with chronic gastritis
and non-identifiable bacteria. PCR can be performed on samples obtained by invasive and
non-invasive methods using samples obtained of saliva, gastric juice, and stools [82, 119]. It is
simple to perform and can provide additional genotypic information about the strain and
antibiotic susceptibilities. PCR could be complete in 3–4 hours, and it is capable to detect the
point mutations attributed to the development of clarithromycin resistance [119, 123].
8.2. Non-invasive tests
Although the gold standard method for diagnosis is gastric histology and rapid urea test, an
important disadvantage is their invasiveness. Non-invasive tests, such as urea breath test
(UBT), serology, and more recently, fecal H. pylori antigen, have been developed and all of
them are feasible in children [50, 119].
8.2.1. Urea breath test (UBT)
UBT is one of the preferred tests to diagnose active H. pylori infection [5, 124]. It is based on
hydrolyses of urea to ammonia and carbon dioxide, which diffuses into the blood and is
excreted by the lungs. Since it requires the child’s full cooperation, it is difficult to perform in
children, especially toddlers and physically challenged [50]. This test is based on the ingestion
of urea labeled with either non-radioactive isotype (C13) or radioactive isotype (C12). The first
is preferred in children [5]. Labeled urea is dissolved in orange juice without sugar, given in
fasting, and the primary objective is to validate C13 in children and adolescents. The ratio in
exhaled air is measured at 0 and then 30 minutes after the intake, and the test is considered
positive when the difference between these two ratios exceeds 4‰ (cut-off value) [124].
Antibiotics must be withheld at least 28 days and proton pump inhibitor (PPI) for 7–14 days
before UBT [5, 82, 124].
8.2.2. Antibody test
The IgG-specific H. pylori antibodies are present in blood nearly 21 days after the infection and
can persist for a long time after eradication therapy. With a sensitivity of 85% and specificity
of 79%, they are not adequate for documenting H. pylori eradication [6, 50].
8.2.3. Fecal antigen test
The fecal antigen test (FAT) identifies H. pylori in stool by enzyme immunoassay (EIA) based
on polyclonal or monoclonal antibodies, and immunochromatographic tests, so-called rapid
or quick tests. The first commercial EIA test to detect H. pylori antigen in stool was the Premier
Platinum HpSA based on polyclonal antibodies. These tests have a wide range of sensitivity
and specificity both in pretreatment (86, 90–98%) and post-treatment (89, 91–92, 95%) [51]. The
stool antigen tests using polyclonal antibodies demonstrated variable results and seem to have
less accuracy than those using monoclonal antibodies. This diagnostic approach is convenient
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for children in whom it is easy to collect feces [117]. Nguyen et al. evaluated the sensitivity
and specificity of monoclonal enzyme stool antigen assay for diagnosis of H. pylori in 232
children age range 3–5 years H. pylori infection positive by culture from biopsies. They found
a sensitivity of 96% and a specificity of 94.8% [125, 126]. FAT can be used to screen for infection
before and after treatment [50, 82, 117]. It is considered as acceptable as UBT and is not
dependent on the child´s collaboration. Recent studies indicate that FAT can be done as early
as 14 days after treatment, but should be done more than 4 weeks [50].
Note: PPI must be withheld two weeks before performing RUT, UBT, and FAT [49, 51]
9. Treatment
The goal of treatment is to obtain 90% eradication. The therapeutic regimens are variable and
dependent on local resistance data. Several studies have documented high resistance to
clarithromycin and metronidazole [127]. The first treatment commonly administered in
children and adults is a triple therapy, for 14 days, that includes a PPI and two antibiotics,
amoxicillin and metronidazole or clarithromycin [49-51, 127]. The first line of recommended
eradication therapies are as follows: amoxicillin, 50 mg/kg twice a day for 14 days; clarithro‐
mycin, 15 mg/kg/twice daily for 14 days; and PPI, 1 mg/kg twice daily for 1 month. Alterna‐
tively, amoxicillin, 50 mg/kg twice a day for 14 days; metronidazole, 20 mg/kg twice daily for
14 days; and PPI, 1 mg/kg twice daily for 1 month or clarithromycin, 15 mg/kg/twice daily for
14 days; metronidazole, 20 mg/kg twice daily for 14 days; and PPI, 1 mg/kg twice daily for 1
month [50]. Several studies revealed that the use of probiotics improves the treatment
tolerance, but there is no evidence of higher eradication [82]. Koletzko et al. [122] revealed a
rate of resistance to clarithromycin of 20%, and a rate of resistance to metronidazole of 23%
after a first treatment [82, 127]. In Portugal, a higher clarithromycin resistance rate was reported
in children (44.8%) compared with adults (14.8%) [127]. The main factors for triple therapy
failure are the low compliance and the bacteria’s resistance to antibiotics. The risk for clari‐
thromycin resistance is related with the previous consumption of macrolides, which is
substantially prescribed in children for respiratory tract diseases. Double resistance strains
were found in up to 50% of strains after failure of therapy using both clarithromycin and
metronidazole [128]. The failure after the first therapeutic approach is predictive of resistance
to other therapeutic approaches [50, 51, 128]. NASPHGAN recommend, in case of failure in
the first line of treatment in children, and if possible, to perform culture with testing for
antibiotic sensitivity to guide a second-line therapy. Other options may be taken if a H.
pylori culture is not possible: quadruple therapy composed of PPI + metronidazole + amoxicillin
+ bismuth, triple therapy using fluoroquinolones, but of limited indication in children, or
sequential therapy involving dual therapy with PPI and amoxicillin for 5 days followed
sequentially by 5 days of triple therapy with PPI, clarithromycin, and metronidazole/tinida‐
zole. In 2005, 74 children (randomized) received sequential therapy and triple therapy.
Eradication was 97.3% in those with sequential therapy compared with 75.7% in children with
triple therapy [51].
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10. Conclusion and possibilities of new studies
Approximately 50% of the world’s population is H. pylori infected. Although it has been a part
of human microbiota, it is classified by The World Health Organization as a gastric carcino‐
genic. H. pylori is acquired essentially in childhood and through mechanisms of escape, it
persists in gastric mucosa for life if left untreated. An association has been found between H.
pylori infection and poverty, low socioeconomic conditions, poor hygiene, and nutritional
deficiencies. With higher prevalence in developing countries, the predisposing factors are the
high number of residents in the same home, sharing the same room or the same bed with H.
pylori-infected children, as well as poor sanitary conditions. Hematological extragastric
disorders have been described as being associated to H. pylori infection. Unexplained ID, IDA,
and refractory IDA in childhood are the most well-known pathologies related to H. pylori
infection. Two meta-analysis have supported the association between H. pylori infection and
IDA, showing an increase of hemoglobin levels after H. pylori eradication [10, 45]. Many areas
of the world have high prevalence of both H. pylori infection and IDA. ID in children leads to
major consequences on children’s health and neurodevelopment. Associations have been
reported, in children, between IDA, lower intelligence scores or cognitive functioning in tests,
and behavioral delays in children, showing that treatment can improve these outcomes [127,
129]. As a result, Update of US Preventive Services Task Force (USPSTF) and the Center for
Disease Control and Prevention recommend screening for IDA in children aged 6–24 months,
between 9 and 12 months, 6 months later, and then annually from the ages of 2 to 5 years,
respectively, and to treat the ID by prescribing 3 mg/kg/day of iron drops between feedings
[129-131]. Refractory to iron therapy implies, after the exclusion of ingestion deficiencies,
hemorrhage, absorption problems, and (rarely) metabolic abnormalities, the search for H.
pylori infection using in the first line non-invasive tests (UBT, FAT, and specific IgG H. pylori
antibodies). All non-invasive tests are feasible in clinical use. C13UBT, with a good sensitivity
for the diagnosis of H. pylori infection, shows limitations such as low specificity for very young
children, being affected by previous ingestion of antibiotics or PPI and the requirement of
patient cooperation [49-51]. Stool antigen test shows low sensitivity and good specificity in
children of all ages, limited also by PPI and antibiotics. It is advisable to validate two non-
invasive tests, the C13UBT and stool antigen for the diagnosis of H. pylori infection in pediatric
ages. Serology is based on the immunological response to chronic H. pylori gastric inflamma‐
tion and is not dependent on antibiotics or on the loading of gastric bacteria. International
Guidelines are well defined regarding IDA in the context of H. pylori infection in childhood,
in which eradication therapy is indicated as it is done in adults. Consensus about the approach
of cTPI and H. pylori infection is well defined in adults, in which H. pylori eradication is followed
by platelet recuperation. In childhood, there is no evidence to support a relationship between
this infection and cTPI. Reports about prevalence of H. pylori and TPI seem to be according to
the epidemiological data of the countries. Contradictory findings with discrepancy in the
response to eradication therapy suggest that in most pediatric cases ITP is primary, with a
spontaneous cure from 6 months to 1 year later, and not secondary to H. pylori infection [87-89].
Maastricht IV and other guidelines suggest not searching for or treating H. pylori in this context.
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Gastric MALT lymphoma is a lymphoid malignancy that is quite rare in children. In these
cases, eradication therapy must be performed regardless of the stage of lymphoma. The failure
of H. pylori eradication is predictive of a resistant strain acquisition and also predictive of
subsequent therapeutic failure. A primary H. pylori resistance in children of European
countries has been estimated and ranges from 12.45 to 23.5% [128]. Therefore, clarithromycin-
based triple therapy can be recommended after studies of antibiotic susceptibility or in
countries with low resistance to clarithromycin. The high resistance of H. pylori to clarithro‐
mycin can justify the use, as first-line therapeutic approach in children, of the sequential
therapy which was referred, resulting in eradication rates of 97.3% against 75.7% with triple
therapy [49, 51]. In children, there are particular problems with alternative antibiotics, which
are not approved for the age. Therefore, they are often treated multiple times without cure.
The impact of this infection on public health implies applying active measures toward H. pylori
eradication. A vaccination strategy should be implemented as the best option to eliminate H.
pylori and therefore to improve public health.
11. New studies
Several new antibiotics are under investigation for the treatment of H. pylori in adults. (1)
Rifabutin. Triple therapy for 10 days with rifabutin + pantoprazole + amoxicillin is showing
good results in resistant H. pylori areas. Resulting in eradication rates of 50% [82, 132]; (2)
Nitazoxanide that includes levofloxacin, nitazoxanide, doxycycline, and omeprazole is
showing better efficacy than standard triple therapy [133].
Author details
Natalina Miguel*
Address all correspondence to: natalina.miguel@gmail.com
Pediatric Department -Trás-os-Montes e Alto-Douro Hospital Center, Vila Real, Portugal
The author has no conflict of interest.
References
[1] Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The
role of Helicobacter pylori infection in hematological disorders. Eur J Intern Med.
2013 Dec;24(8):685-90. PubMed PMID: 23523153. Epub 2013/03/26. eng.
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827
99
[2] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with
gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):1311-5. PubMed PMID:
6145023. Epub 1984/06/16. eng.
[3] Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter py‐
lori infection in the United States. Am J Epidemiol. 2006 Jan 15;163(2):127-34.
PubMed PMID: 16306309. Epub 2005/11/25. eng.
[4] Rajindrajith S, Devanarayana NM, de Silva HJ. Helicobacter pylori infection in chil‐
dren. Saudi J Gastroenterol. 2009 Apr;15(2):86-94. PubMed PMID: 19568571. Pubmed
Central PMCID: PMC2702974. Epub 2009/07/02. eng.
[5] Sherman P, Hassall E, Hunt RH, Fallone CA, Veldhuyzen Van Zanten S, Thomson
AB. Canadian Helicobacter Study Group Consensus Conference on the Approach to
Helicobacter pylori Infection in Children and Adolescents. Can J Gastroenterol. 1999
Sep;13(7):553-9. PubMed PMID: 10519952. Epub 1999/10/16. eng.
[6] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr
Eval Carcinog Risks Hum. 1994;61:1-241. PubMed PMID: 7715068. Epub 1994/01/01.
eng.
[7] Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases.
EMBO Rep. 2006 Oct;7(10):956-60. PubMed PMID: 17016449. Pubmed Central
PMCID: PMC1618379. Epub 2006/10/04. eng.
[8] Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection.
Clin Microbiol Rev. 2006 Jul;19(3):449-90. PubMed PMID: 16847081. Pubmed Central
PMCID: PMC1539101. Epub 2006/07/19. eng.
[9] Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-as‐
sociated gastritis and primary B-cell gastric lymphoma. Lancet. 1991 Nov 9;338(8776):
1175-6. PubMed PMID: 1682595. Epub 1991/11/09. eng.
[10] Pacifico L, Osborn JF, Tromba V, Romaggioli S, Bascetta S, Chiesa C. Helicobacter py‐
lori infection and extragastric disorders in children: a critical update. World J Gastro‐
enterol. 2014 Feb 14;20(6):1379-401. PubMed PMID: 24587617. Pubmed Central
PMCID: PMC3925850. Epub 2014/03/04. eng.
[11] Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J. Variable hematologic
presentation of autoimmune gastritis: age-related progression from iron deficiency to
cobalamin depletion. Blood. 2006 Feb 15;107(4):1673-9. PubMed PMID: 16239424.
Epub 2005/10/22. eng.
[12] Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, et al.
Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or
unexplained iron deficiency anemia. Haematologica. 2005 May;90(5):585-95. PubMed
PMID: 15921373. Epub 2005/06/01. eng.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview100
[13] Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency ane‐
mia. Blood. 2014 Jan 16;123(3):326-33. PubMed PMID: 24215034. Epub 2013/11/12.
eng.
[14] Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos
DP. Helicobacter pylori and autoimmune disease: cause or bystander. World J Gas‐
troenterol. 2014 Jan 21;20(3):613-29. PubMed PMID: 24574735. Pubmed Central
PMCID: PMC3921471. Epub 2014/02/28. eng.
[15] Ertem D. Helicobacter pylori infection in children. Journal of Pediatric Sciences.
2011;3(4)(e 102):1-15.
[16] Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection.
World J Gastroenterol. 2014 Sep 28;20(36):12818-38. PubMed PMID: 25278680.
Pubmed Central PMCID: PMC4177465. Epub 2014/10/04. eng.
[17] Smith SM. Role of Toll-like receptors in Helicobacter pylori infection and immunity.
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):133-46. PubMed PMID:
25133016. Pubmed Central PMCID: PMC4133513. Epub 2014/08/19. eng.
[18] Smith SM, Moran AP, Duggan SP, Ahmed SE, Mohamed AS, Windle HJ, et al. Trib‐
bles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter py‐
lori lipopolysaccharide. J Immunol. 2011 Feb 15;186(4):2462-71. PubMed PMID:
21220698. Epub 2011/01/12. eng.
[19] Michalkiewicz J, Helmin-Basa A, Grzywa R, Czerwionka-Szaflarska M, Szaflarska-
Poplawska A, Mierzwa G, et al. Innate immunity components and cytokines in gas‐
tric mucosa in children with Helicobacter pylori infection. Mediators Inflamm.
2015;2015:176726. PubMed PMID: 25948881. Pubmed Central PMCID: PMC4407632.
Epub 2015/05/08. eng.
[20] Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune
defenses. Clin Microbiol Rev. 2009 Apr;22(2):240-73, Table of Contents. PubMed
PMID: 19366914. Pubmed Central PMCID: Pmc2668232. Epub 2009/04/16. eng.
[21] Peek RM, Jr., Fiske C, Wilson KT. Role of innate immunity in Helicobacter pylori-in‐
duced gastric malignancy. Physiol Rev. 2010 Jul;90(3):831-58. PubMed PMID:
20664074. Pubmed Central PMCID: Pmc2990353. Epub 2010/07/29. eng.
[22] Wang JQ, Jeelall YS, Ferguson LL, Horikawa K. Toll-Like Receptors and Cancer:
MYD88 Mutation and Inflammation. Front Immunol. 2014;5:367. PubMed PMID:
25132836. Pubmed Central PMCID: PMC4116802. Epub 2014/08/19. eng.
[23] Bliss CM, Jr., Golenbock DT, Keates S, Linevsky JK, Kelly CP. Helicobacter pylori lip‐
opolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial
neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human
monocytes. Infect Immun. 1998 Nov;66(11):5357-63. PubMed PMID: 9784544.
Pubmed Central PMCID: PMC108670. Epub 1998/10/24. eng.
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827
101
[24] Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease.
Curr Opin Immunol. 2009 Feb;21(1):38-46. PubMed PMID: 19230638. Pubmed Cen‐
tral PMCID: Pmc2723941. Epub 2009/02/24. eng.
[25] Roe K, Gibot S, Verma S. Triggering receptor expressed on myeloid cells-1 (TREM-1):
a new player in antiviral immunity? Front Microbiol. 2014;5:627. PubMed PMID:
25505454. Pubmed Central PMCID: Pmc4244588. Epub 2014/12/17. eng.
[26] Schmausser B, Endrich S, Beier D, Moran AP, Burek CJ, Rosenwald A, et al. Trigger‐
ing receptor expressed on myeloid cells-1 (TREM-1) expression on gastric epitheli‐
um: implication for a role of TREM-1 in Helicobacter pylori infection. Clin Exp
Immunol. 2008 Apr;152(1):88-94. PubMed PMID: 18321350. Pubmed Central PMCID:
Pmc2384064. Epub 2008/03/07. eng.
[27] Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, et al. The
neutrophil-activating protein of Helicobacter pylori promotes Th1 immune respons‐
es. J Clin Invest. 2006 Apr;116(4):1092-101. PubMed PMID: 16543949. Pubmed Cen‐
tral PMCID: PMC1401483. Epub 2006/03/18. eng.
[28] Larussa T, Leone I, Suraci E, Imeneo M, Luzza F. Helicobacter pylori and T Helper
Cells: Mechanisms of Immune Escape and Tolerance. J Immunol Res.
2015;2015:981328. PubMed PMID: 26525279. Pubmed Central PMCID: PMC4615206.
Epub 2015/11/04. eng.
[29] Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seropreva‐
lence and ethnic differences in Helicobacter pylori infection among adults in the
United States. J Infect Dis. 2000 Apr;181(4):1359-63. PubMed PMID: 10762567. Epub
2000/04/14. eng.
[30] Franceschi F, Annalisa T, Teresa DR, Giovanna D, Ianiro G, Franco S, et al. Role of
Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol.
2014 Sep 28;20(36):12809-17. PubMed PMID: 25278679. Pubmed Central PMCID:
Pmc4177464. Epub 2014/10/04. eng.
[31] Nguyen VB, Nguyen TAX, Nguyen TVA, PHAM DP, Hoang TH, Phung DC. Epi‐
demiology of helicobacter pylori infection in Kinh and Khmer Children in Mekong
Delta, Vietnam. Ann Clin Lab Res. 2015:1-9.
[32] Mitchel H. Epidemiology of Infection. In: HLT M, GL M, SL H, editors. Helicobacter
pylori: Physiology and Genetics: Washington (DC): ASM Press; 2001.
[33] Cherian S, Forbes D, Sanfilippo F, Cook A, Burgner D. The epidemiology of Helico‐
bacter pylori infection in African refugee children resettled in Australia. Med J Aust.
2008 Oct 20;189(8):438-41. PubMed PMID: 18928436. Epub 2008/10/22. eng.
[34] Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol
Rev. 2000;22(2):283-97. PubMed PMID: 11218379. Epub 2001/02/24. eng.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview102
[35] Goodman KJ, Correa P, Tengana Aux HJ, DeLany JP, Collazos T. Nutritional factors
and Helicobacter pylori infection in Colombian children. J Pediatr Gastroenterol
Nutr. 1997 Nov;25(5):507-15. PubMed PMID: 9360204. Epub 1997/11/14. eng.
[36] Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, Perez-Perez GI, et al.
Asthma is inversely associated with Helicobacter pylori status in an urban popula‐
tion. PLoS One. 2008;3(12):e4060. PubMed PMID: 19112508. Pubmed Central PMCID:
PMC2603593. Epub 2008/12/30. eng.
[37] Amedei A, Codolo G, Del Prete G, de Bernard M, D'Elios MM. The effect of Helico‐
bacter pylori on asthma and allergy. J Asthma Allergy. 2010;3:139-47. PubMed PMID:
21437048. Pubmed Central PMCID: Pmc3047919. Epub 2010/01/01. eng.
[38] Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterolo‐
gy. 2005 May;128(6):1579-605. PubMed PMID: 15887153. Epub 2005/05/12. eng.
[39] Hulten K, Han SW, Enroth H, Klein PD, Opekun AR, Gilman RH, et al. Helicobacter
pylori in the drinking water in Peru. Gastroenterology. 1996 Apr;110(4):1031-5.
PubMed PMID: 8612990. Epub 1996/04/01. eng.
[40] Fan XG, Chua A, Li TG, Zeng QS. Survival of Helicobacter pylori in milk and tap wa‐
ter. J Gastroenterol Hepatol. 1998 Nov;13(11):1096-8. PubMed PMID: 9870794. Epub
1998/12/31. eng.
[41] Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori
from healthy infected adults. JAMA. 1999 Dec 15;282(23):2240-5. PubMed PMID:
10605976. Epub 1999/12/22. eng.
[42] Ferguson DA, Jr., Li C, Patel NR, Mayberry WR, Chi DS, Thomas E. Isolation of Heli‐
cobacter pylori from saliva. J Clin Microbiol. 1993 Oct;31(10):2802-4. PubMed PMID:
8253990. Pubmed Central PMCID: Pmc266021. Epub 1993/10/01. eng.
[43] Handt LK, Fox JG, Dewhirst FE, Fraser GJ, Paster BJ, Yan LL, et al. Helicobacter pylo‐
ri isolated from the domestic cat: public health implications. Infect Immun. 1994 Jun;
62(6):2367-74. PubMed PMID: 8188360. Pubmed Central PMCID: Pmc186520. Epub
1994/06/01. eng.
[44] Roesler BM, Rabelo-Goncalves EM, Zeitune JM. Virulence Factors of Helicobacter py‐
lori: A Review. Clin Med Insights Gastroenterol. 2014;7:9-17. PubMed PMID:
24833944. Pubmed Central PMCID: PMC4019226. Epub 2014/05/17. eng.
[45] Pacifico L, Anania C, Osborn JF, Ferraro F, Chiesa C. Consequences of Helicobacter
pylori infection in children. World J Gastroenterol. 2010 Nov 7;16(41):5181-94.
PubMed PMID: 21049552. Pubmed Central PMCID: Pmc2975089. Epub 2010/11/05.
eng.
[46] Rogers LM, Boy E, Miller JW, Green R, Rodriguez M, Chew F, et al. Predictors of co‐
balamin deficiency in Guatemalan school children: diet, Helicobacter pylori, or bacte‐
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827
103
rial overgrowth? J Pediatr Gastroenterol Nutr. 2003 Jan;36(1):27-36. PubMed PMID:
12499993. Epub 2002/12/25. eng.
[47] Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lympho‐
ma: old and new insights. Ann Gastroenterol. 2014;27(1):27-33. PubMed PMID:
24714739. Pubmed Central PMCID: Pmc3959547. Epub 2014/04/10. Eng.
[48] Konturek SJ, Konturek PC, Pieniazek P, Bielanski W. Role of Helicobacter pylori in‐
fection in extragastroduodenal disorders: introductory remarks. J Physiol Pharmacol.
1999 Dec;50(5):683-94. PubMed PMID: 10695551. Epub 2000/03/01. eng.
[49] Malfertheiner P, F. M, C. OM. Guidelines for the management of Helicobacter pylori
Infection. European Gastroenterol Review. 2005:59-999.
[50] Chey WD, Wong BC. American College of Gastroenterology guideline on the man‐
agement of Helicobacter pylori infection. Am J Gastroenterol. 2007 Aug;102(8):
1808-25. PubMed PMID: 17608775. Epub 2007/07/05. eng.
[51] Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, et al. Evidence-
based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection
in children. J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):230-43. PubMed PMID:
21558964. Epub 2011/05/12. eng.
[52] Gupta V, Eden AJ, Mills MJ. Helicobacter pylori and autoimmune neutropenia. Clin
Lab Haematol. 2002 Jun;24(3):183-5. PubMed PMID: 12067285. Epub 2002/06/18. eng.
[53] Papadaki HA, Pontikoglou C, Eliopoulos DG, Pyrovolaki K, Spyridaki R, Eliopoulos
GD. Helicobacter pylori infection is probably the cause of chronic idiopathic neutro‐
penia (CIN)-associated splenomegaly. Am J Hematol. 2006 Feb;81(2):142-4. PubMed
PMID: 16432851. Epub 2006/01/25. eng.
[54] Qu XH, Huang XL, Xiong P, Zhu CY, Huang YL, Lu LG, et al. Does Helicobacter py‐
lori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastro‐
enterol. 2010 Feb 21;16(7):886-96. PubMed PMID: 20143469. Pubmed Central PMCID:
PMC2825337. Epub 2010/02/10. eng.
[55] Dufour C, Brisigotti M, Fabretti G, Luxardo P, Mori PG, Barabino A. Helicobacter py‐
lori gastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr.
1993 Aug;17(2):225-7. PubMed PMID: 8229554. Epub 1993/08/01. eng.
[56] Gasbarrini A, Franceschi F, Armuzzi A, Ojetti V, Candelli M, Torre ES, et al. Extradi‐
gestive manifestations of Helicobacter pylori gastric infection. Gut. 1999 Jul;45 Suppl
1:I9-i12. PubMed PMID: 10457029. Pubmed Central PMCID: Pmc1766655. Epub
1999/08/24. eng.
[57] Kearney DJ. Helicobacter pylori infection and iron deficiency anemia: accumulating
evidence in support of a real association. Indian J Gastroenterol. 2005 Jul-Aug;24(4):
147-50. PubMed PMID: 16204900. Epub 2005/10/06. eng.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview104
[58] Jain S, Das S, Gupta P. Fecal occult blood screening in children with severe malnutri‐
tion. Indian Pediatr. 2007 Dec;44(12):913-5. PubMed PMID: 18175844. Epub
2008/01/08. eng.
[59] Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull.
1998;54(1):139-50. PubMed PMID: 9604438. Epub 1998/05/30. eng.
[60] Rieder G, Einsiedl W, Hatz RA, Stolte M, Enders GA, Walz A. Comparison of CXC
chemokines ENA-78 and interleukin-8 expression in Helicobacter pylori-associated
gastritis. Infect Immun. 2001 Jan;69(1):81-8. PubMed PMID: 11119492. Pubmed Cen‐
tral PMCID: Pmc97858. Epub 2000/12/19. eng.
[61] Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler
MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation.
Blood. 2007 Jan 1;109(1):353-8. PubMed PMID: 16946298. Epub 2006/09/02. eng.
[62] Cherian S, Forbes DA, Cook AG, Sanfilippo FM, Kemna EH, Swinkels DW, et al. An
insight into the relationships between hepcidin, anemia, infections and inflammatory
cytokines in pediatric refugees: a cross-sectional study. PLoS One. 2008;3(12):e4030.
PubMed PMID: 19107209. Pubmed Central PMCID: Pmc2603326. Epub 2008/12/25. eng.
[63] Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004
May;113(9):1251-3. PubMed PMID: 15124013. Pubmed Central PMCID: Pmc398435.
Epub 2004/05/05. eng.
[64] Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropri‐
ate expression of hepcidin is associated with iron refractory anemia: implications for the
anemia  of  chronic  disease.  Blood.  2002  Nov  15;100(10):3776-81.  PubMed  PMID:
12393428. Epub 2002/10/24. eng.
[65] Lee SY, Song EY, Yun YM, Yoon SY, Cho YH, Kim SY, et al. Serum prohepcidin levels in
Helicobacter pylori infected patients with iron deficiency anemia. Korean J Intern Med.
2010  Jun;25(2):195-200.  PubMed  PMID:  20526394.  Pubmed  Central  PMCID:
Pmc2880694. Epub 2010/06/09. eng.
[66] Baysoy G,  Ertem D, Ademoglu E,  Kotiloglu E,  Keskin S,  Pehlivanoglu E.  Gastric
histopathology, iron status and iron deficiency anemia in children with Helicobacter
pylori infection. J Pediatr Gastroenterol Nutr. 2004 Feb;38(2):146-51. PubMed PMID:
14734875. Epub 2004/01/22. eng.
[67] Przybyszewska J, Zekanowska E. The role of hepcidin, ferroportin, HCP1, and DMT1
protein in iron absorption in the human digestive tract. Prz Gastroenterol. 2014;9(4):
208-13.  PubMed  PMID:  25276251.  Pubmed  Central  PMCID:  Pmc4178046.  Epub
2014/10/03. eng.
[68] Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of in‐
flammation. Blood. 2003 Aug 1;102(3):783-8. PubMed PMID: 12663437. Epub
2003/03/29. eng.
[69] Kim HK, Jang EC, Yeom JO, Kim SY, Cho H, Kim SS, et al. Serum prohepcidin levels
are lower in patients with atrophic gastritis. Gastroenterol Res Pract.
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827
105
2013;2013:201810. PubMed PMID: 23533385. Pubmed Central PMCID: Pmc3603588.
Epub 2013/03/28. eng.
[70] Harris PR, Serrano CA, Villagran A, Walker MM, Thomson M, Duarte I, et al. Helico‐
bacter pylori-associated hypochlorhydria in children, and development of iron defi‐
ciency. J Clin Pathol. 2013 Apr;66(4):343-7. PubMed PMID: 23268321. Epub
2012/12/27. eng.
[71] Sarker SA, Davidsson L, Mahmud H, Walczyk T, Hurrell RF, Gyr N, et al. Helico‐
bacter pylori infection, iron absorption, and gastric acid secretion in Bangladeshi
children. Am J Clin Nutr. 2004 Jul;80(1):149-53. PubMed PMID: 15213042. Epub
2004/06/24. eng.
[72] Modlin IM, Kidd M, Marks IN, Tang LH. The pivotal role of John S. Edkins in the
discovery of gastrin. World J Surg. 1997 Feb;21(2):226-34. PubMed PMID: 8995084.
Epub 1997/02/01. eng.
[73] Korman MG, Strickland RG, Hansky J. Serum gastrin in chronic gastritis. Br Med J.
1971 Apr 3;2(5752):16-8. PubMed PMID: 5550864. Pubmed Central PMCID:
Pmc1795895. Epub 1971/04/03. eng.
[74] Hartman KR, Barker JA. Microcytic anemia with iron malabsorption: an inherited
disorder of iron metabolism. Am J Hematol. 1996 Apr;51(4):269-75. PubMed PMID:
8602626. Epub 1996/04/01. eng.
[75] Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron
deficiency anemia patients with H pylori-positive chronic gastristis. World J Gastroen‐
terol. 2007 Oct 28;13(40):5380-3. PubMed PMID: 17879411. Pubmed Central PMCID:
PMC4171331. Epub 2007/09/20. eng.
[76] Park JH, Kim SY, Kim DW, Lee WG, Rhee KH, Youn HS. Correlation between Helicobact‐
er pylori infection and vitamin C levels in whole blood, plasma, and gastric juice, and the
pH of gastric juice in Korean children. J Pediatr Gastroenterol Nutr. 2003 Jul;37(1):
53-62. PubMed PMID: 12827006. Epub 2003/06/27. eng.
[77] Zhang ZW, Patchett SE, Perrett D, Katelaris PH, Domizio P, Farthing MJ. The relation
between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity
in the human stomach. Gut. 1998 Sep;43(3):322-6. PubMed PMID: 9863475. Pubmed
Central PMCID: Pmc1727232. Epub 1998/12/24. eng.
[78] Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G, et al.
Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with
asymptomatic gastritis. Ann Intern Med. 1999 Nov 2;131(9):668-72. PubMed PMID:
10577329. Epub 1999/11/30. eng.
[79] Zhang ZW, Abdullahi M, Farthing MJ. Effect of physiological concentrations of vita‐
min C on gastric cancer cells and Helicobacter pylori. Gut. 2002 Feb;50(2):165-9. PubMed
PMID: 11788554. Pubmed Central PMCID: Pmc1773094. Epub 2002/01/15. eng.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview106
[80] Annibale B, Capurso G, Lahner E, Passi S, Ricci R, Maggio F, et al. Concomitant alter‐
ations in intragastric pH and ascorbic acid concentration in patients with Helicobact‐
er pylori gastritis and associated iron deficiency anaemia. Gut. 2003 Apr;52(4):
496-501. PubMed PMID: 12631657. Pubmed Central PMCID: PMC1773597. Epub
2003/03/13. eng.
[81] Senkovich O, Ceaser S, McGee DJ, Testerman TL. Unique host iron utilization mecha‐
nisms of Helicobacter pylori revealed with iron-deficient chemically defined media.
Infect Immun. 2010 May;78(5):1841-9. PubMed PMID: 20176792. Pubmed Central
PMCID: Pmc2863533. Epub 2010/02/24. eng.
[82] Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori
pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014 Sep 28;20(36):
12781-808. PubMed PMID: 25278678. Pubmed Central PMCID: Pmc4177463. Epub
2014/10/04. eng.
[83] Dogan Y, Erkan T, Onal Z, Usta M, Dogusoy G, Cokugras FC, et al. Lactoferrin levels
in the gastric tissue of Helicobacter pylori-positive and -negative patients and its ef‐
fect on anemia. Mediators Inflamm. 2012;2012:214581. PubMed PMID: 22529520.
Pubmed Central PMCID: Pmc3316978. Epub 2012/04/25. eng.
[84] Gold BD, Gilger MA, Czinn SJ. New Diagnostic Strategies for Detection of Helico‐
bacter pylori Infection in Pediatric Patients. Gastroenterol Hepatol (N Y). 2014 Dec;
10(12 Suppl 7):1-19. PubMed PMID: 26491414. Pubmed Central PMCID: Pmc4606978.
Epub 2015/10/23. eng.
[85] Mazzucco KL, Junior LM, Lemos NE, Wieck A, Pezzi A, Laureano AM, et al. Assess‐
ment of regulatory T cells in childhood immune thrombocytopenic purpura. ISRN
Hematol. 2013;2013:143687. PubMed PMID: 24298390. Pubmed Central PMCID:
Pmc3835721. Epub 2013/12/04. eng.
[86] Celkan T. Changes in childhood ITP treatment and follow-up in 2011. 2012.
[87] Wilson D. Acquired platelets defects. In: Sciences EH, editor. Nathan and Oski's
Hematology of Infancy and Childhood 7th edition. 12009. p. 1553-90.
[88] Evim MS, Baytan B, Gunes AM. Childhood Immune Thrombocytopenia: Long-term
Follow-up Data Evaluated by the Criteria of the International Working Group on Im‐
mune Thrombocytopenic Purpura. Turk J Haematol. 2014 Mar;31(1):32-9. PubMed
PMID: 24764727. Pubmed Central PMCID: Pmc3996642. Epub 2014/04/26. eng.
[89] Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. In‐
ternational consensus report on the investigation and management of primary im‐
mune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. PubMed PMID: 19846889.
Epub 2009/10/23. eng.
[90] Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical fea‐
tures and pathogenic mechanisms. World J Gastroenterol. 2014 Jan 21;20(3):714-23.
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827
107
PubMed PMID: 24574745. Pubmed Central PMCID: Pmc3921481. Epub 2014/02/28.
eng.
[91] Nugent DJ. Immune thrombocytopenic purpura of childhood. Hematology Am Soc
Hematol Educ Program. 2006:97-103. PubMed PMID: 17124046. Epub 2006/11/25.
eng.
[92] Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiol‐
ogy of immune thrombocytopenia. Semin Hematol. 2013 Jan;50 Suppl 1:S43-9.
PubMed PMID: 23664516. Epub 2013/05/17. eng.
[93] McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakar‐
yocyte production by antiplatelet autoantibodies from adult patients with chronic
ITP. Blood. 2004 Feb 15;103(4):1364-9. PubMed PMID: 14576051. Epub 2003/10/25.
eng.
[94] Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Im‐
mune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoan‐
tibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003 Aug 1;102(3):887-95.
PubMed PMID: 12676790. Epub 2003/04/05. eng.
[95] Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J
Haematol. 2006 May;133(4):364-74. PubMed PMID: 16643442. Epub 2006/04/29. eng.
[96] Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ, et al.
Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce
platelet aggregation. Gastroenterology. 2003 Jun;124(7):1846-54. PubMed PMID:
12806618. Epub 2003/06/14. eng.
[97] Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytope‐
nia. Semin Hematol. 2009 Jan;46(1 Suppl 2):S2-14. PubMed PMID: 19245930. Pubmed
Central PMCID: Pmc2682438. Epub 2009/03/31. eng.
[98] Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter py‐
lori eradication on platelet count in idiopathic thrombocytopenic purpura: a system‐
atic review and meta-analysis. J Antimicrob Chemother. 2007 Aug;60(2):237-46.
PubMed PMID: 17561502. Epub 2007/06/15. eng.
[99] Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y. Effects of a Helico‐
bacter pylori eradication regimen on anti-platelet autoantibody response in infected
and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica.
2006 Oct;91(10):1436-7. PubMed PMID: 16963398. Epub 2006/09/12. eng.
[100] Rajantie J, Klemola T. Helicobacter pylori and idiopathic thrombocytopenic purpura
in children. Blood. 2003 Feb 15;101(4):1660. PubMed PMID: 12560248. Epub
2003/02/01. eng.
[101] Stasi R, Provan D. Helicobacter pylori and Chronic ITP. Hematology Am Soc Hema‐
tol Educ Program. 2008:206-11. PubMed PMID: 19074084. Epub 2008/12/17. eng.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview108
[102] Yamanishi S, Iizumi T, Watanabe E, Shimizu M, Kamiya S, Nagata K, et al. Implica‐
tions for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori
urease. Infect Immun. 2006 Jan;74(1):248-56. PubMed PMID: 16368978. Pubmed Cen‐
tral PMCID: Pmc1346662. Epub 2005/12/22. eng.
[103] Yeh JJ, Tsai S, Wu DC, Wu JY, Liu TC, Chen A. P-selectin-dependent platelet aggre‐
gation and apoptosis may explain the decrease in platelet count during Helicobacter
pylori infection. Blood. 2010 May 27;115(21):4247-53. PubMed PMID: 20097880. Epub
2010/01/26. eng.
[104] Andersson P-O, Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP):
molecular mechanisms and implications for therapy. Expert Reviews in Molecular
Medicine. 2004;6(24):1-17.
[105] Troppan K, Wenzl K, Neumeister P, Deutsch A. Molecular Pathogenesis of MALT
Lymphoma. Gastroenterol Res Pract. 2015;2015:102656. PubMed PMID: 25922601.
Pubmed Central PMCID: Pmc4397421. Epub 2015/04/30. eng.
[106] Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML. Non-Hodg‐
kin's lymphoma of mucosa-associated lymphoid tissue. Oncologist. 2006 Nov-Dec;
11(10):1100-17. PubMed PMID: 17110630. Epub 2006/11/18. eng.
[107] Claviez A, Meyer U, Dominick C, Beck JF, Rister M, Tiemann M. MALT lymphoma
in children: a report from the NHL-BFM Study Group. Pediatr Blood Cancer. 2006
Aug;47(2):210-4. PubMed PMID: 16123999. Epub 2005/08/27. eng.
[108] Hasosah M, Baothman A, Satti M, Kutbi S, Alghamdi K, Jacobson K. Mucosa-associ‐
ated lymphoid tissue lymphoma of the lacrimal gland: sustained remission after
eradication of helicobacter pylori infection. Case Rep Gastrointest Med.
2011;2011:945752. PubMed PMID: 22606434. Pubmed Central PMCID: Pmc3350112.
Epub 2011/01/01. eng.
[109] Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid
tissue. Toxicol Pathol. 2006;34(5):599-608. PubMed PMID: 17067945. Epub 2006/10/28.
eng.
[110] Gisbert JP, Calvet X. Review article: common misconceptions in the management of
Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther.
2011 Nov;34(9):1047-62. PubMed PMID: 21919927. Epub 2011/09/17. eng.
[111] Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regres‐
sion of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid
tissue type after eradication of Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):
575-7. PubMed PMID: 8102719. Epub 1993/09/04. eng.
[112] Wu TC, Chen LK, Lai CR. Primary gastric lymphoma associated with Helicobacter
pylori in a child. J Pediatr Gastroenterol Nutr. 2001 May;32(5):608-10. PubMed PMID:
11429527. Epub 2001/06/29. eng.
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827
109
[113] Liu H, Ye H, Dogan A, Ranaldi R, Hamoudi RA, Bearzi I, et al. T(11;18)(q21;q21) is
associated with advanced mucosa-associated lymphoid tissue lymphoma that ex‐
presses nuclear BCL10. Blood. 2001 Aug 15;98(4):1182-7. PubMed PMID: 11493468.
Epub 2001/08/09. eng.
[114] Zucca E, Roggero E, Pileri S. B-cell lymphoma of MALT type: a review with special
emphasis on diagnostic and management problems of low-grade gastric tumours. Br
J Haematol. 1998 Jan;100(1):3-14. PubMed PMID: 9450784. Epub 1998/02/05. eng.
[115] Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma
of MALT type. Blood. 2000 Jul 15;96(2):410-9. PubMed PMID: 10887100. Epub
2000/07/11. eng.
[116] Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and non-inva‐
sive tests. Best Pract Res Clin Gastroenterol. 2007;21(2):299-313. PubMed PMID:
17382278. Epub 2007/03/27. eng.
[117] Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility
testing. Clin Microbiol Rev. 2007 Apr;20(2):280-322. PubMed PMID: 17428887.
Pubmed Central PMCID: Pmc1865594. Epub 2007/04/13. eng.
[118] van IMC, Laheij RJ, de Boer WA, Jansen JB. The importance of corpus biopsies for the
determination of Helicobacter pylori infection. Neth J Med. 2005 Apr;63(4):141-5.
PubMed PMID: 15869042. Epub 2005/05/05. eng.
[119] Garza-Gonzalez E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A re‐
view of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.
World J Gastroenterol. 2014 Feb 14;20(6):1438-49. PubMed PMID: 24587620. Pubmed
Central PMCID: Pmc3925853. Epub 2014/03/04. eng.
[120] Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test.
Ann Transl Med. 2015 Jan;3(1):9. PubMed PMID: 25705641. Pubmed Central PMCID:
Pmc4293486. Epub 2015/02/24. eng.
[121] Koumi A, Filippidis T, Leontara V, Makri L, Panos MZ. Detection of Helicobacter py‐
lori: A faster urease test can save resources. World J Gastroenterol. 2011 Jan 21;17(3):
349-53. PubMed PMID: 21253394. Pubmed Central PMCID: Pmc3022295. Epub
2011/01/22. eng.
[122] Siavoshi F, Saniee P, Khalili-Samani S, Hosseini F, Malakutikhah F, Mamivand M, et
al. Evaluation of methods for H. pylori detection in PPI consumption using culture,
rapid urease test and smear examination. Ann Transl Med. 2015 Jan;3(1):11. PubMed
PMID: 25705643. Pubmed Central PMCID: Pmc4293475. Epub 2015/02/24. eng.
[123] Chisholm SA, Owen RJ, Teare EL, Saverymuttu S. PCR-based diagnosis of Helico‐
bacter pylori infection and real-time determination of clarithromycin resistance di‐
rectly from human gastric biopsy samples. J Clin Microbiol. 2001 Apr;39(4):1217-20.
PubMed PMID: 11283030. Pubmed Central PMCID: Pmc87913. Epub 2001/04/03. eng.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview110
[124] Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helico‐
bacter pylori infection. Gut. 1999 Jul;45 Suppl 1:I18-22. PubMed PMID: 10457031.
Pubmed Central PMCID: Pmc1766662. Epub 1999/08/24. eng.
[125] Tiryaki Z, Yilmaz-Ciftdogan D, Kasirga E. Diagnostic value of stool antigen and anti‐
body tests for Helicobacter pylori infection in Turkish children with upper gastroin‐
testinal complaints before and after eradication. Turk J Pediatr. 2010 Sep-Oct;52(5):
505-11. PubMed PMID: 21434536. Epub 2011/03/26. eng.
[126] Nguyen TV, Bengtsson C, Nguyen GK, Granstrom M. Evaluation of a novel mono‐
clonal-based antigen-in-stool enzyme immunoassay (Premier Platinum HpSA PLUS)
for diagnosis of Helicobacter pylori infection in Vietnamese children. Helicobacter.
2008 Aug;13(4):269-73. PubMed PMID: 18665935. Epub 2008/07/31. eng.
[127] Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, et al. Prospective
multicentre study on antibiotic resistance of Helicobacter pylori strains obtained
from children living in Europe. Gut. 2006 Dec;55(12):1711-6. PubMed PMID:
16603633. Pubmed Central PMCID: Pmc1856474. Epub 2006/04/11. eng.
[128] Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in
testing. Gut. 2004 Sep;53(9):1374-84. PubMed PMID: 15306603. Pubmed Central
PMCID: Pmc1774187. Epub 2004/08/13. eng.
[129] Siu AL. Screening for Iron Deficiency Anemia in Young Children: USPSTF Recom‐
mendation Statement. Pediatrics. 2015 Oct;136(4):746-52. PubMed PMID: 26347426.
Epub 2015/09/09. eng.
[130] WHO. Iron deficiency anaemia: assessment, prevention and control - A guide for
programme managers 2001. Available from: http://www.who.int/iris/bitstream/
10665/66914/http://apps.who.int//iris/bitstream/10665/66914/1/WHO_NHD_01.3.pdf?
ua=1.
[131] Recommendations to prevent and control iron deficiency in the United States. Cen‐
ters for Disease Control and Prevention. MMWR Recomm Rep. 1998 Apr 3;47(Rr-3):
1-29. PubMed PMID: 9563847. Epub 1998/05/01. eng.
[132] Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, et al. Rescue Therapy with a Proton
Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A
Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2015;2015:415648.
PubMed PMID: 26106411. Pubmed Central PMCID: PMC4461753. Epub 2015/06/25.
eng.
[133] Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized
study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus tri‐
ple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011 Nov;
106(11):1970-5. PubMed PMID: 21989146. Pubmed Central PMCID: PMC3209586.
Epub 2011/10/13. eng.
Hematological Extradigestive Manifestations of Helicobacter pylori Infection in Childhood
http://dx.doi.org/10.5772/63827

